UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended December 31, 2011

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition period from to

Commission file number 001-32935

ARCADIA RESOURCES, INC.

(Exact name of registrant as specified in its charter)

NEVADA		88-0331369
(State or other jurisdiction of Incorporation)		(I.R.S. Employer Identification Number)

9320 PRIORITY WAY WEST DRIVE
INDIANAPOLIS, INDIANA		46240
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (317) 569-8234

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes R No £

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a smaller reporting company (as defined in Exchange Act Rule 12b-2).

Large Accelerated filer £

Accelerated filer £

Non-accelerated filer R

Smaller Reporting Company £

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes £ No R

As of February 20, 2012, 193,450,000 shares of common stock, $0.001 par value, of the Registrant were outstanding.

Table of Contents

	Page No.
Part I: Financial Information

Item 1. Financial Statements
Condensed Consolidated Balance Sheets as of December 31, 2011 (unaudited) and March 31, 2011	2
Condensed Consolidated Statements of Operations for the Three and Nine Months ended December 31, 2011 and 2010 (unaudited)	3
Condensed Consolidated Statement of Stockholders’ Deficit for the Nine Months ended December 31, 2011 (unaudited)	4
Condensed Consolidated Statements of Cash Flows for the Nine Months ended December 31, 2011 and 2010 (unaudited)	5
Notes to the Condensed Consolidated Financial Statements (unaudited)	6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3. Quantitative and Qualitative Disclosures About Market Risk	38
Item 4. Controls and Procedures	39


Part II: Other Information

Item 1. Legal Proceedings	40
Item 1A. Risk Factors	40
Item 5. Other Information	46
Item 6. Exhibits	46
Signatures	47

Exhibits
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Table of Contents

PART I. – FINANCIAL INFORMATION

Item 1. Financial Statements

ARCADIA RESOURCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)

	December 31,			March 31,
	2011			2011
ASSETS	(unaudited)

Current assets:
Cash and cash equivalents	$	-		$	2,136
Accounts receivable, net of allowance of $1,815 and $1,499, respectively		11,495			10,620
Prepaid expenses and other current assets		1,787			965
Current assets of discontinued operations		1,613			2,714
Total current assets		14,895			16,435
Property and equipment, net		194			313
Acquired intangible assets, net		-			7,098
Other assets		49			345
Restricted cash		-			1,000
Assets of discontinued operations		791			940
Total assets	$	15,929		$	26,131

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Outstanding checks in excess of deposits	$	296		$	-
Accounts payable		1,247			715
Line of credit		9,456			-
Accrued expenses:
Compensation and related taxes		1,999			2,562
Interest		56			35
Health claims		325			756
Other		1,380			789
Fair value of warrant liability		14			285
Payable to affiliated agencies		409			616
Long-term obligations, current portion		30,548			-
Capital lease obligations, current portion		-			4
Current liabilities of discontinued operations		5,773			1,114
Total current liabilities		51,503			6,876
Line of credit		-			7,129
Long-term obligations, less current portion		-			27,807
Liabilities of discontinued operations		-			4,375
Total liabilities		51,503			46,187

Commitments and contingencies

STOCKHOLDERS’ DEFICIT
Preferred stock, $.001 par value, 5,000,000 shares authorized, none outstanding		-			-
Common stock, $.001 par value, 300,000,000 shares authorized; 193,450,044 shares and 193,162,544 shares issued, respectively		193			193
Additional paid-in capital		151,680			151,436
Accumulated deficit		(187,447	)		(171,685	)
Total stockholders’ deficit		(35,574	)		(20,056	)
Total liabilities and stockholders’ deficit	$	15,929		$	26,131

See accompanying notes to these condensed consolidated financial statements.

Table of Contents

ARCADIA RESOURCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

	Three Month Period Ended December 31,						Nine Month Period Ended December 31,
	(Unaudited)						(Unaudited)
	2011			2010			2011			2010

Revenue	$	20,644		$	21,139		$	61,504		$	62,434
Cost of revenues		14,541			14,733			43,291			43,646
Gross profit		6,103			6,406			18,213			18,788

Selling, general and administrative		6,295			6,727			20,819			21,350
Depreciation and amortization		157			254			542			752
Goodwill and intangible asset impairment		7,786			-			7,786			-
Total operating expenses		14,238			6,981			29,147			22,102

Operating loss		(8,135	)		(575	)		(10,934	)		(3,314	)

Other expenses:
Interest expense, net		950			872			2,762			2,497
Change in fair value of warrant liability		(14	)		(541	)		(271	)		(678	)
Total other expenses		936			331			2,491			1,819

Loss from continuing operations before income taxes		(9,071	)		(906	)		(13,425	)		(5,133	)

Income tax expense		19			30			60			102
Loss from continuing operations		(9,090	)		(936	)		(13,485	)		(5,235	)

Discontinued operations:
Loss from discontinued operations		(800	)		(1,610	)		(3,118	)		(5,294	)
Net gain on disposal		114			228			841			1,274
Total discontinued operations		(686	)		(1,382	)		(2,277	)		(4,020	)

NET LOSS	$	(9,776	)	$	(2,318	)	$	(15,762	)	$	(9,255	)

Weighted average number of common shares outstanding		193,341			187,309			193,303			180,627

Basic and diluted net loss per share:
Loss from continuing operations	$	(0.05	)	$	-		$	(0.07	)	$	(0.03	)
Loss from discontinuing operations		-			(0.01	)		(0.01	)		(0.02	)
Net loss per share	$	(0.05	)	$	(0.01	)	$	(0.08	)	$	(0.05	)

See accompanying notes to these condensed consolidated financial statements.

Table of Contents

ARCADIA RESOURCES, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(IN THOUSANDS, EXCEPT SHARE AMOUNTS)

(Unaudited)

					Additional					Total
	Common Stock				Paid-In		Accumulated			Stockholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance, April 1, 2011		193,162,544	$	193	$	151,436	$	(171,685	)	$	(20,056	)
Stock-based compensation expense		287,500		-		244		-			244
Net loss for the period		-		-		-		(15,762	)		(15,762	)
Balance, December 31, 2011		193,450,044	$	193	$	151,680	$	(187,447	)	$	(35,574	)

See accompanying notes to these condensed consolidated financial statements.

Table of Contents

ARCADIA RESOURCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

	Nine Month Period Ended
	December 31,
	(Unaudited)
	2011			2010
Operating activities
Net loss for the period	$	(15,762	)	$	(9,255	)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts		639			534
Depreciation of property and equipment		366			540
Amortization of intangible assets		388			429
Goodwill and intangible asset impairment		7,786			-
Gain on business disposals		(841	)		(1,274	)
Non-cash interest expense		2,148			2,141
Amortization of deferred financing costs and debt discounts		302			291
Stock-based compensation expense		244			1,056
Change in fair value of warrant liability		(271	)		(678	)
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable		(954	)		(711	)
Inventories		370			(315	)
Other assets		(652	)		(116	)
Accounts payable		1,043			(1,677	)
Accrued expenses		(442	)		(896	)
Due to affiliated agencies		(178	)		(569	)
Net cash used in operating activities		(5,814	)		(10,500	)

Investing activities
Business acquisitions, net of cash acquired		(371	)		(140	)
Proceeds from business disposal		841			1,342
(Increase) decrease in restricted cash		1,000			(500	)
Purchases of property and equipment		(98	)		(473	)
Net cash provided by investing activities		1,372			229

Financing activities
Net borrowings on lines of credit		2,326			4,947
Proceeds from equity financing, net of fees paid in cash of $536		-			4,476
Payments on notes payable and capital lease obligations		(20	)		(802	)
Proceeds from exercise of stock options		-			2
Net cash provided by financing activities		2,306			8,623

Net change in cash and cash equivalents		(2,136	)		(1,648	)
Cash and cash equivalents, beginning of period		2,136			5,444
Cash and cash equivalents, end of period	$	-		$	3,796

Supplementary information:

Cash paid during the period for:
Interest	$	440		$	395
Income taxes		60			102

Non-cash investing / financing activities:
Accrued interest converted to notes payable		2,148			2,141

See accompanying notes to these consolidated financial statements.

Table of Contents

ARCADIA RESOURCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1 – Description of Company and Significant Accounting Policies

Description of Company

Arcadia Resources, Inc., a Nevada corporation, together with its wholly-owned subsidiaries (the “Company”), is a national provider of home care, medical staffing and pharmacy services operating under the service mark Arcadia HealthCare. As of December 31, 2011, the Company operated in two reportable business segments: Home Care/Medical Staffing Services (“Services”) and Pharmacy. The Company’s corporate headquarters are located in Indianapolis, Indiana, and the Services segment customer services center is located in Southfield, Michigan. On December 6, 2011, the Company entered into an agreement to sell substantially all of the assets of its Pharmacy segment, and this transaction was completed on February 17, 2012.

See “Note 2 – Management’s Plan” for a discussion about the Company’s anticipated future plans and alternatives for the remaining business.

Unaudited Interim Financial Information

The accompanying consolidated balance sheet as of December 31, 2011, the consolidated statements of operations for the three and nine month periods ended December 31, 2011 and 2010, the consolidated statements of cash flows for the nine month periods ended December 31, 2011 and 2010, and the consolidated statement of stockholders’ deficit for the nine month period ended December 31, 2011, are unaudited but include all adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of our financial position at such dates and the results of operations and cash flows for the periods then ended, in conformity with accounting principles generally accepted in the United States (“GAAP”). The consolidated balance sheet as of March 31, 2011 has been derived from the audited consolidated financial statements at that date but, in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”), does not include all of the information and notes required by GAAP for complete financial statements. Operating results for the three and nine month periods ended December 31, 2011 are not necessarily indicative of results that may be expected for the entire fiscal year. The financial statements should be read in conjunction with the financial statements and notes for the fiscal year ended March 31, 2011 included in the Company’s Form 10-K filed with the SEC on June 28, 2011.

Reclassifications

Certain amounts presented in the prior period have been reclassified to conform to current period presentations including the reflection of newly discontinued operations separately from continuing operations.

Recent Accounting Pronouncements

In May 2011, the FASB provided an accounting standards update to FASB Accounting Standards Codification Topic 820, “Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs.” The amendments in this update result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRSs. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, the FASB does not intend for the amendments in this update to result in a change in the application of the requirements in Topic 820. Some of the amendments clarify the FASB’s intent about the application of existing fair value measurement requirements. Other amendments change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements. The application of this guidance did not have a material impact on the Company’s consolidated financial statements presentation.

Table of Contents

Note 2 – Management’s Plan

On February 17, 2012, the Company sold substantially all of the assets of its Pharmacy segment to Medication Adherence Solutions, LLC (“MAS”), a subsidiary of The Walgreen Co. The cash proceeds of $2.0 million were paid by MAS directly to H.D. Smith Wholesale Drug Co. (“H.D. Smith”) pursuant to the terms of the Secured Creditor Assignment and Release Agreement dated as of December 6, 2011 (the “Secured Creditor Agreement”). In addition, MAS assumed or paid at closing trade payables of the Pharmacy segment of approximately $1.5 million. The Company received no cash proceeds from this transaction. For a further description of the terms of the sale of the Pharmacy segment assets, see “Note 3 – Discontinued Operations”.

As a result of this transaction, the Company no longer operates the Pharmacy segment as of February 17, 2012. The Pharmacy segment was previously reported as a discontinued operation.

The Company’s sole remaining line of business is its Services segment, which consists of its Home Care and Medical Staffing business. The Company’s Board of Directors continues to consider options with respect to the Services segment. The costs associated with being a public company are significant, and the Company is likely to have negative cash flow in the near term with no immediate access to additional equity or debt funding.

In addition, the Company has approximately $40.0 million in debt that matures April 1, 2012, which as of December 31, 2011 included approximately $9.5 million due to Comerica Bank under the line of credit agreement (the “Comerica Credit Line”) that funds the operations of the Services segment (the “Comerica Debt”) and approximately $30.5 million in unsecured promissory notes of Arcadia Resources, Inc. (“the ARI Debt”). The Company does not anticipate that it will be able to repay or refinance the ARI Debt at maturity and, therefore, the holders of the ARI Debt may declare the debt to be in default. For a further description of the outstanding debt of the Company, see “Note 7 – Long Term Obligations”.

As a result of the above, the Company is continuing to pursue the sale of the Services business and is in on-going discussions with a number of parties regarding the potential sale.

While the Services segment is not in compliance with certain covenants under the Comerica Credit Line, the Comerica Debt has not been accelerated and Comerica continues to provide funding for the Services segment operations. The Company anticipates that Comerica will continue to provide funding to the Services segment until the business is sold. However, at any time Comerica has the right to accelerate the maturity of the Comerica Debt and declare the outstanding principal amount to be immediately due and payable. In addition, the indebtedness under the Comerica Credit Line matures and becomes due and payable on April 1, 2012. For a further description of the status of the Comerica Credit Line, see “Note 6 – Line of Credit”.

If the Services segment is sold, the Company anticipates that the Comerica Debt will be assumed by the purchaser of the Services segment or repaid by the purchaser at closing. While the Company may realize sale proceeds in excess of the Comerica Debt from the sale of the Services segment, such proceeds are not expected to be sufficient to repay or refinance the ARI Debt. In such event, the Company would no longer have any operating businesses, would not be a going concern, and its liabilities would substantially exceed its tangible assets.

If the Services segment is not sold, the Company will need to renegotiate and extend the maturity of the Comerica Debt and the ARI Debt. There can be no assurances that the Company would be able to renegotiate and extend the maturity of this debt. Moreover, the Company would need to significantly improve its cash flow through increased revenue, additional cost reductions and operational improvements.

For these reasons, investors are strongly discouraged from trading in the Company’s common stock because it is highly unlikely that there is any equity value related to the common shares.

Table of Contents

Note 3 – Discontinued Operations

Pharmacy Segment

Pursuant to an Asset Purchase Agreement by and among PrairieStone Pharmacy, LLC (“PrairieStone”), the Company and Medication Adherence Solutions, LLC (“MAS”) dated as of December 6, 2011 (the “APA”), on February 17, 2012 the Company and PrairieStone sold substantially all of the operating assets of the Company’s Pharmacy segment, which includes the DailyMedTM Pharmacy business, to MAS. The assets purchased by MAS included accounts receivable and/or the proceeds from the collection of such accounts, equipment, inventory, assumed contracts and leases, intellectual property and intangible personal property used in or for the benefit of the Pharmacy segment business. MAS paid $2.0 million cash at closing, which payment went directly to H.D. Smith, the secured lender to the Pharmacy segment as more fully described in the “Line of Credit – Discontinued Operations” section below. In addition, MAS assumed or paid at closing trade payables to vendors of the Pharmacy segment in the amount of $1.5 million. Subsequent to the Closing, the parties to the APA have agreed to make an adjustment to the purchase price based upon the Working Capital Balance (as defined in the APA) at closing. The working capital adjustment will be made if the Working Capital Balance exceeds or is less than $400,000, subject to the provision that no working capital adjustment shall be made unless the amount of the adjustment exceeds $50,000.

The closing of the sale pursuant to the APA on February 17, 2012 also became the Effective Date under the Secured Creditor Assignment and Release Agreement between PrairieStone, the Company, H.D. Smith and MAS dated as of December 6, 2011 (the “Secured Creditor Agreement”). Pursuant to the Secured Creditor Agreement, as of the Effective Date, H.D. Smith received the $2.0 million cash payment at closing from MAS and H.D. Smith agreed that there shall be no further amounts owed to them by PrairieStone or the Company under the Line of Credit and Security Agreement dated as of April 23, 2010 and the loan documents and agreements related thereto (the “HD Smith Loan Agreements”). In addition, H.D. Smith (i) assigned to MAS all claims and liabilities (the “Assigned Claims”) that H.D. Smith held or may assert against PrairieStone under the H.D. Smith Loan Agreements, (ii) released, discharged and terminated any and all security interests in the assets of PrairieStone and the PrairieStone member interests pledged by the Company, (iii) terminated the H.D. Smith Loan Agreements (including the Company’s guaranty of PrairieStone’s indebtedness to HD Smith), the Forbearance Agreement and the Prime Vendor Agreement dated as of April 23, 2010 (“PVA”), (iv) terminated its outstanding common stock purchase warrants, (v) released the Company and PrairieStone from any claims related to the H.D. Smith Loan Agreements, the Forbearance Agreement and the PVA, and (vi) permitted MAS for a period not to exceed six (6) months to purchase pharmaceutical products and supplies on the same conditions and terms as set forth in the PVA. In addition, the Secured Creditor Agreement provides that MAS will not bring any claim or cause of action against the Company or PrairieStone with respect to the Assigned Claims, except that MAS may (x) file a claim in any bankruptcy or insolvency proceeding filed by, against or concerning PrairieStone or (y) assert the Assigned Claims defensively, including as an offset, in certain third-party actions. H.D. Smith also released back to the Company $100,000 held as a collateral security deposit pursuant to the Forbearance Agreement.

The Management Services Agreement by and between the Company and MAS dated as of December 6, 2011 (the “Management Agreement”), also became effective upon the closing of the sale under the APA. Under the Management Agreement, the Company is providing management services to MAS. The Company will receive a monthly management fee of $25,000 for the management services provided. The Company has designated Marvin Richardson, the Company’s CEO and President, as the Manager under the Management Agreement, and, as such, he will assist MAS with the day-to-day supervision and management of the business for and on behalf of MAS. The Management Agreement will be in effect from February 17, 2012 until the earlier of (i) May 17, 2012 and (ii) the date the Company and Marvin Richardson agree that Marvin Richardson no longer is to be employed by the Company as CEO and President and MAS and Mr. Richardson agree that he is to be employed by MAS or its affiliates. MAS has offered to employ Mr. Richardson as Director of Pharmacy Operations – DailyMedTM subsequent to the Closing and following the termination or expiration of the Management Agreement. Mr. Richardson has accepted the offer of employment.

As provided in the APA, MAS entered into an agreement to lease certain space in the Company’s Indianapolis, Indiana facility previously occupied by the Pharmacy segment from the building owner. The Company agreed to terminate the lease of the remaining space occupied by the Company’s corporate office, and the building owner released the Company from any future obligations under the lease. As partial consideration for the building owner’s release of the Company, the Company agreed to release to the building owner $250,000 held in escrow as a security deposit. The Company continues to maintain its Corporate offices at this location.

In March 2011, the Company ceased the majority of its operations at its Minnesota pharmacy and began reflecting the ceased operations as discontinued operations in the consolidated financial statements. A portion of the business and the majority of the Minnesota assets were transferred to the Indianapolis, Indiana pharmacy location. The cost to close the Minnesota facility was immaterial.

Table of Contents

Services Segment

On May 29, 2009, the Company finalized the sale of substantially all of the assets of its industrial and non-medical staffing business, which had been part of the Services segment, for cash proceeds of $250,000, which were paid in five equal installments through September 2009. Additionally, the Company was to receive 50% of the future earnings of the business until the total payments equal $1,600,000. During fiscal 2011 and 2010, the Company received $759,000 in total earn out payments. During the nine month period ended December 31, 2011, the Company received the remaining $841,000 in earn out payments. Due to the uncertainty about the ultimate collectability, the potential earn out payments were not originally recorded as receivables at the time of the transaction. All earn out payments were recorded as additional gain on the transaction.

HHE Segment

On May 18, 2009, the Company completed the sale of its ownership interest in Lovell Medical Supply, Inc., Beacon Respiratory Services of Georgia, Inc., and Trinity Healthcare of Winston-Salem, Inc. to Aerocare Holdings, Inc. for total proceeds of $4,750,000, less fees of $150,000. In May 2010, the Company received the final payment of $155,000. This payment was recognized as an additional gain on the sale during the nine month period ended December 31, 2010.

On May 19, 2009, the Company entered into an Asset Purchase Agreement with Braden Partners, L.P. to sell the assets of its Midwest region of the Company’s HHE business. Total proceeds were $4,000,000, less fees of $150,000. $1,000,000 of the purchase price was held by the buyer to cover the Company’s contingent obligations. Subsequent to the transaction date, the buyer made certain claims, and in June 2010, the Company received a final settlement payment of $500,000 to resolve these claims. This payment was recognized as an additional gain on the sale during the nine month period ended December 31, 2010.

As of May 2009, the Company had sold all of its HHE operations.

Catalog Segment

On October 1, 2010, the Company completed the sale of its ownership interest in Rite at Home Health Care Products, LLC to Home Health Depot, Inc. The Company recorded a loss of $123,000 during fiscal 2011 in conjunction with this disposal. This entity represented the Company’s Catalog segment.

Prior to their actual disposal, the assets and liabilities associated with these discontinued business operations have been classified as assets and liabilities of discontinued operations in the accompanying consolidated balance sheets. The results of the above businesses are reported in discontinued operations in the accompanying consolidated statements of operations, and the prior period consolidated statements of operations have been recast to conform to this presentation. The discontinued operations do not reflect the costs of certain services provided to these operations by the Company. Such costs, which were not allocated by the Company to the various operations, included internal employee costs associated with administrative functions, including accounting, information technology, human resources, compliance and contracting as well as external costs for legal fees, insurance, audit fees, payroll processing, and various public-company expenses. The Company uses a centralized approach to cash management and financing of its operations, and, accordingly, unsecured debt and the related interest expense were also not allocated specifically to these operations. The consolidated statements of cash flows do not separately report the cash flows of the discontinued operations.

Table of Contents

The components of the assets and liabilities of the discontinued operations are presented below (in thousands):

	December 31, 2011		March 31, 2011
	Pharmacy		Pharmacy
Assets
Accounts receivable, net of allowance of $468 and $399, respectively	$	869	$	1,430
Inventories, net		425		795
Prepaid expenses and other current assets		319		489
Total current assets of discontinued operations		1,613		2,714
Property and equipment, net		791		940
Total non-current assets of discontinued operations		791		940
Total assets of discontinued operations	$	2,404	$	3,654

Liabilities
Accounts payable	$	918	$	514
Line of credit (in default)		4,521		-
Accrued compensation and related taxes		131		230
Accrued health claims		76		100
Accrued other		121		60
Capital lease obligations, current portion		6		21
Long-term obligations, current portion		-		189
Total current liabilities of discontinued operations		5,773		1,114
Line of credit		-		4,375
Total liabilities of discontinued operations	$	5,773	$	5,489

The components of the earnings/(loss) from discontinued operations by segment are presented below (in thousands):

	Three Month Period Ended December 31, 2011
	Services		Pharmacy			Total

Revenues, net	$	-	$	4,316		$	4,316
Cost of revenue		-		3,764			3,764
Gross profit		-		552			552

Selling, general and administrative		-		1,203			1,203
Depreciation and amortization		-		71			71
Total operating expenses		-		1,274			1,274

Interest expense		-		78			78

Loss from operations		-		(800	)		(800	)
Net gain on disposal		114		-			114

Earnings (loss) from discontinued operations	$	114	$	(800	)	$	(686	)

Table of Contents

	Three Month Period Ended December 31, 2010
	Services			Pharmacy			Catalog			Total

Revenues, net	$	-		$	5,033		$	-		$	5,033
Cost of revenue		-			4,219			-			4,219
Gross profit		-			814			-			814

Selling, general and administrative		7			2,177			29			2,213
Depreciation and amortization		-			80			-			80
Total operating expenses		7			2,257			29			2,293

Interest expense		-			131			-			131

Loss from operations		(7	)		(1,574	)		(29	)		(1,610	)
Net gain (loss) on disposal		292			-			(64	)		228

Earnings (loss) from discontinued operations	$	285		$	(1,574	)	$	(93	)	$	(1,382	)

	Nine Month Period Ended December 31, 2011
	Services		Pharmacy			Total

Revenues, net	$	-	$	13,249		$	13,249
Cost of revenue		-		11,475			11,475
Gross profit		-		1,774			1,774

Selling, general and administrative		-		4,337			4,337
Depreciation and amortization		-		212			212
Total operating expenses		-		4,549			4,549

Interest expense		-		343			343

Loss from operations		-		(3,118	)		(3,118	)
Net gain on disposal		841		-			841

Earnings (loss) from discontinued operations	$	841	$	(3,118	)	$	(2,277	)

Table of Contents

	Nine Month Period Ended December 31, 2010
	Services			Pharmacy			HHE		Catalog			Total

Revenues, net	$	-		$	14,998		$	-	$	660		$	15,658
Cost of revenue		-			12,759			-		397			13,156
Gross profit		-			2,239			-		263			2,502

Selling, general and administrative		7			6,868			-		374			7,249
Depreciation and amortization		-			217			-		-			217
Total operating expenses		7			7,085			-		374			7,466

Interest expense		-			330			-		-			330

Loss from operations		(7	)		(5,176	)		-		(111	)		(5,294	)
Net gain (loss) on disposal		683			-			655		(64	)		1,274

Earnings (loss) from discontinued operations	$	676		$	(5,176	)	$	655	$	(175	)	$	(4,020	)

Impairment Expense – Discontinued Operations

In accordance with our policy, the Company performs its annual impairment review during the fiscal fourth quarter. As part of the fourth quarter fiscal 2011 Pharmacy goodwill impairment analysis, the Company recognized that the growth from the DailyMed program continued to be slower than anticipated and that there was uncertainty surrounding the timing and amount of future revenue and cash flow streams. The Company determined that it was appropriate to write off the remaining goodwill balance and recorded a $2,500,000 impairment charge. The Company had previously recognized a $13,217,000 goodwill impairment relating to the Pharmacy segment in conjunction with the fiscal 2009 goodwill impairment analysis.

Line of Credit – Discontinued Operations

The following table summarizes the line of credit for the Pharmacy segment (in thousands):

		At December 31, 2011
Lending Institution	Maturity date	Maximum Available Borrowing		Balance			March 31,2011			Interest rate
H.D. Smith	April 23, 2013		4,777		4,777			4,777			7	%
Unamortized debt discount					(256	)		(402	)
					4,521			4,375
Less current portion in default					(4,521	)		-
				$	-		$	4,375

On April 23, 2010, the Company’s wholly-owned subsidiary, PrairieStone Pharmacy, LLC (“PrairieStone”) executed a Line of Credit and Security Agreement (the “HD Smith Credit Agreement”) with HD Smith Wholesale Drug Co. (“HD Smith”), its primary supplier of pharmaceutical products. Under terms of the HD Smith Credit Agreement, PrairieStone was permitted to borrow up to $5,000,000, including amounts payable under normal product purchasing terms. Beginning April 1, 2011, additional borrowings under the agreement were limited based upon a borrowing base of the assets. The debt accrues interest at the greater of 7% and the prime rate plus 3%. Interest during the first 12 months of the agreement was added to the debt balance. Interest only payments are required from May 2011 through April 2012. The debt is secured by all of the tangible and intangible assets of PrairieStone and is guaranteed by the Company. The agreement includes certain financial covenants for the Pharmacy segment beginning with the fiscal fourth quarter 2012. Specifically, the financial covenants are as follows: positive quarterly earnings before income tax, depreciation and amortization and current assets divided by current liabilities of greater than .75. As of December 31, 2011, there was no additional availability under the line.

In conjunction with the HD Smith Credit Agreement, the Company issued HD Smith certain warrants to purchase common stock (see “Note 8 - Stockholders’ Deficit” for more details) and incurred certain professional fees. These costs, which originally totaled $561,000, were recorded as a debt discount and are being amortized over the term of the debt agreement.

Table of Contents

On September 29, 2011, the Company and PrairieStone received a letter from HD Smith indicating that PrairieStone was in default of its obligations under the HD Smith Credit Agreement. HD Smith declared all principal and accrued interest to be immediately due and payable. In lieu of exercising certain rights and remedies under the loan agreements, HD Smith, the Company and PrairieStone entered into a forbearance agreement dated October 6, 2011 (the "Forbearance Agreement"). During the Forbearance Period (as defined below), HD Smith agreed to forbear from exercising its rights under the HD Smith Credit Agreement for a limited period of time to permit the Company and PrairieStone to seek a purchaser for all of PrairieStone’s DailyMed business. On December 6, 2011 and simultaneous with the execution of the Asset Purchase Agreement (“APA”) more fully described in “Note 3 – Discontinued Operations”, the Company and PrairieStone entered into a Secured Creditor Assignment and Release Agreement (“Secured Creditor Agreement”) with HD Smith and Medication Adherence Solutions. The Secured Creditor Agreement provided for HD Smith to receive the $2.0 million cash payment contemplated in the APA. The Company received no cash proceeds from MAS as part of the transaction. Additionally, H.D. Smith assigned to MAS its right to payment of all amounts due under the H.D. Smith Credit Agreement, less the $2.0 million cash payment (“Assigned Claims”). MAS has agreed that it will not assert any claims or causes of action against PrairieStone or the Company to collect the Assigned Claims except under limited circumstances set forth in the Secured Creditor Agreement as set forth above in “Note 3 – Discontinued Operations.”

Note 4 – Fair Value

Effective April 1, 2008, the Company adopted accounting guidance that established a framework for measuring fair value and expanded disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. Fair value is to be determined based on assumptions that market participants would use in pricing an asset or liability. Current authoritative accounting guidance uses a three-tier hierarchy that classifies assets and liabilities based on the inputs used in the valuation methodologies. In accordance with this guidance, the Company measures its warrant liability at fair value. Management classified these as Level 3 liabilities, as they are based on unobservable inputs and involve management judgement.

The following table presents a reconciliation of warrant liabilities measured at fair value on a recurring basis at December 31, 2011 (in thousands):

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Warrant Liability
Balance at April 1, 2010	$	1,499
Warrants issued		273
Reclassification to permanent equity		(35	)
Decrease in market value		(1,452	)
Balance at March 31, 2011		285
Decrease in market value		(271	)
Balance at December 31, 2011	$	14

Table of Contents

Note 5 – Goodwill and Acquired Intangible Assets

The following table presents the detail of the changes in goodwill for the period ended December 31, 2011 (in thousands):

Goodwill at April 1, 2011	$	-
Acquisitions during the period		1,076
Impairment expense		(1,076	)
Goodwill at December 31, 2011	$	-

For tax purposes, goodwill of approximately $16.4 million is amortizable over 15 years while the remainder of the Company’s goodwill is not amortizable as the acquisitions related to the purchase of common stock rather than of assets or net assets.

On December 31, 2011, the Company recognized a full impairment charge on the remaining value of the goodwill asset, which is more fully described below.

Acquired intangible assets consist of the following (in thousands):

	December 31, 2011					March 31, 2011
				Accumulated					Accumulated
	Cost			Amortization		Cost			Amortization
Trade name	$	6,664		$	1,146	$	6,664		$	1,016
Customer relationships		4,720			3,528		4,720			3,270
		11,384		$	4,674		11,384		$	4,286
Less accumulated amortization		(4,674	)				(4,286	)
Net acquired intangible assets		6,710					7,098
Impairment expense		(6,710	)				-
	$	-				$	7,098

Amortization expense for acquired intangible assets included in continuing operations was $129,000 and $143,000 for the three month periods ending December 31, 2011 and 2010, respectively, and $388,000 and $429,000 for the nine month periods ending December 31, 2011 and 2010, respectively. On December 31, 2011, the Company recognized a full impairment charge on the remaining value of the acquired intangible assets, which is more fully described below.

Impairment Expense

In accordance with our policy, the Company performs its annual goodwill impairment review during the fiscal fourth quarter. Management tests for goodwill impairment between annual impairment assessments if events occur or circumstances change that would more likely than not reduce the fair value of the business below its carrying amount. Examples of such events or circumstances include, but are not limited to, the following: (i) a significant adverse change in business climate; (ii) an adverse action or assessment by a regulator; (iii) unanticipated competition; or (iv) a decline in the market capitalization below net book value. Additionally, the Company reviews its amortizable long-lived assets for impairment whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

Based on the decline in the Company’s market capitalization and the near term cash flow projections, management determined that it was appropriate to perform an impairment assessment of goodwill and the amortizable intangible assets as of December 31, 2011. Management has been in discussions with various parties regarding the possible sale of the Services segment for the last several quarters. Based on these discussions and on the near-term cash flow projections, management determined that a complete impairment of the goodwill and acquired intangible assets was appropriate. As such, the Company recognized $1,076,000 and $6,710,000 of goodwill and intangible asset impairment, respectively.

During fiscal 2009 and 2010, the Services business as a whole had seen declining revenue, and the decline was primarily driven by a decline in the medical staffing and travel staffing businesses. Many of the Service’s locations provided both home care and medical staffing services. During fiscal 2010, home care accounted for 79% of total segment revenue and medical staffing and travel staffing, in the aggregate, accounted for the remaining 21% of revenue. The medical staffing and travel staffing business experienced a 46% decline in revenue from fiscal 2008 to fiscal 2010. During the same period, home care revenue increased by 9%, but fiscal 2010 revenue was approximately 1% lower than fiscal 2009. Management’s ability to predict the timing and extent of the segments recovery was subject to some uncertainty. Therefore, management focused on more recent trends in its annual impairment analysis, which resulted in lower future cash flow projections than in prior years’ analysis. The impairment analysis resulted in a $14,599,000 goodwill impairment charge for fiscal 2010.

Table of Contents

Note 6 – Line of Credit

At December 31, 2011

Lending Institution

Maturity date

Maximum Available Borrowing

Balance

March 31,2011

Interest rate

Comerica Bank

April 1, 2012

9,456

7,129

Prime plus 2.75%

Arcadia Services, Inc. (“ASI”), a wholly-owned subsidiary of the Company, and three of ASI’s wholly-owned subsidiaries (the “Services Borrowers”) have an outstanding line of credit agreement with Comerica Bank. As of December 31, 2011, advances under the line of credit agreement cannot exceed the lesser of the revolving credit commitment amount of $11 million or the aggregate principal amount of indebtedness permitted under the advance formula amount at any one time. The advance formula base is 85% of the eligible accounts receivable, plus the lesser of 85% of eligible unbilled accounts or $3,000,000. The line of credit agreement contains a subjective acceleration clause and requires the Company to maintain a lockbox. However, Services Borrowers have the ability to control the funds in the deposit account and to determine the amount used to pay down the line of credit balance. As such, the line of credit has not been automatically classified as a current obligation. The Services Borrowers agreed to various financial covenant ratios (as described below), to have any person who acquires ASI’s capital stock to pledge such stock to Comerica Bank, and to customary negative covenants. The line of credit agreement had previously required Services Borrowers to maintain a deposit account with a minimum balance, and this amount was classified as restricted cash on the Company’s consolidated balance sheet. If an event of default occurs, Comerica Bank may, at its option, accelerate the maturity of the debt and exercise its right to foreclose on the issued and outstanding capital stock of ASI and on all of the assets of Services Borrowers. On December 31, 2011, the interest rate on this line of credit agreement was the bank’s prime rate plus 2.75% (6.0%), and the availability under the line was $0.

RKDA, Inc. (“RKDA”), a wholly-owned subsidiary of the Company and the owner of all the outstanding capital stock of ASI, granted Comerica Bank a first priority security interest in all of the issued and outstanding capital stock of ASI. ASI granted Comerica Bank a first priority security interest in all of its assets. The other Services Borrowers also granted the bank security interests in all of their assets. RDKA is restricted from paying dividends to the Company. RKDA executed a guaranty to Comerica Bank for all indebtedness of Services Borrowers.

On October 31, 2010 and in conjunction with a covenant violation, the Company and the bank entered into an amendment and waiver agreement. The amendment reduced the revolving credit commitment amount from $14 million to $11 million and extended the maturity date to April 1, 2012. The amendment also established new covenant requirements. Specifically, the following financial covenants apply: tangible effective net worth of $750,000 as of December 31, 2010 and gradually increasing on a quarterly basis to $1.25 million by March 31, 2012 (the “TNW Covenant”); minimum quarterly net income of $400,000 (the “Net Income Covenant”); and, minimum subordination of indebtedness to the Company of $9.15 million (the “Subordinated Debt Covenant”). Finally, the amendment increased the required restricted cash balance from $500,000 to $1,000,000.

On a monthly basis, the Company submits ASI financial information to Comerica. On September 13, 2011, the Services Borrowers received a letter from Comerica stating that the Services Borrowers failed to comply with certain covenants under the credit agreement because as of July 31, 2011, the Services Borrowers failed to be in compliance with the Subordinated Debt Covenant. Because of the events described in the notice letter, Comerica informed the Services Borrowers that Comerica has no obligation to make further advances under the credit facility and that future advances shall be subject to the sole discretion of Comerica. Comerica has not sought to accelerate the repayment of the indebtedness or to foreclose on any of the security interests as set forth above. While Comerica continues to make advances under the credit facility and the Company expects that advances will continue to be made, there can be no assurances that Comerica will exercise its discretion to make further advances or that Comerica will not accelerate the repayment of the indebtedness. Should Comerica not continue to provide advances under the credit facility, the Company and the Services Borrowers would not have access to the funds needed to operate the business. In such event, the Company would be forced to consider alternative sources of liquidity to operate the business, which may require them to commence a proceeding under the federal bankruptcy laws to cause Comerica to provide access funds under the Credit Agreement.

As of December 31, 2011, the Services Borrowers were not in compliance with the TNW Covenant, the Net Income Covenant or the Subordinated Debt Covenant. The non-compliance with the TNW Covenant and the Net Income Covenant was caused in part by the charge taken by the Company in connection with the proposed settlement of a pending class action lawsuit as more fully described in “Note 9 – Contingencies” and the impairment charges discussed in “Note 5 – Goodwill and Acquired Intangible Assets” above.

The Services Borrowers are presently in discussion with Comerica on the terms of a forbearance agreement related to the Comerica credit facility. In the interim, Comerica continues to provide funding to ASI and to pay certain corporate expenses of the Company. In October 2011, Comerica released the $1,000,000 of restricted cash to the Services Borrowers to fund their business operations. The Services Borrowers believe they will enter into a forbearance agreement with Comerica and continue to access the Comerica credit facility while pursuing the strategic alternatives for the business discussed in “Note 2 – Management’s Plan”.

Table of Contents

Note 7 – Long-Term Obligations

Long-term obligations consist of the following (in thousands):

	December 31,			March 31,
	2011			2011
Note payable to JANA Master Fund, Ltd. ("JANA") in the original amount of $18.0 million, dated March 25, 2009 bearing an effective interest rate of 10% with unpaid accrued interest and principal due in full on April 1, 2012. Cash interest that would otherwise be payable on such quarterly interest payment dates may be added to the principal balance of the note payable at the Company's option. The note payable is unsecured.	$	20,905		$	19,406

Note payable to Vicis Capital Master Fund ("Vicis") in the original amount of $7.8 million, dated March 25, 2009 bearing an effective interest rate of 10% with unpaid accrued interest and principal due in full on April 1, 2012. Cash interest that would otherwise be payable on such quarterly interest payment dates may be added to the principal balance of the note payable at the Company's option. The note payable is unsecured.		7,735			7,181

Note payable to LSP Partners, LP ("LSP") in the amount of $1.0 million, dated March 25, 2009 bearing an effective interest rate of 10% with unpaid accrued interest and principal due in full on April 1, 2012. Cash interest that would otherwise be payable on such quarterly interest payment dates may be added to the principal balance of the note payable at the Company's option. The note payable is unsecured.		1,315			1,220

Note payable to BestCare Travel Staffing LLC dated April 4, 2011 bearing an effective interest rate of 10% due April 1, 2012. Interest only payments due monthly. The note payable is unsecured. The maturity of the note is subject to acceleration upon the divestiture of the Services segment or the consummation of a financing transaction in excess of $5 million.		593			-

Total long-term obligations		30,548			27,807
Less current portion of long-term obligations		(30,548	)		-
Long-term obligations, less current portion	$	-		$	27,807

On March 25, 2009, the Company entered into a Master Exchange Agreement with JANA (related entity), Vicis (related entity) and LSP. Pursuant to the agreement, Vicis purchased $2,000,000 of the principal balance of promissory note held by JANA. Additionally, JANA and LSP advanced the Company $2,000,000 and $1,000,000 of cash, respectively. JANA and Vicis then exchanged their previously outstanding promissory notes for new notes with terms as described above. The new promissory notes due to JANA, Vicis, and LSP include covenants relating to, among other items, limitations of additional indebtedness, issuance of new equity securities and the application of proceeds from future asset sales. Specifically, the notes provide that the first $2,000,000 in proceeds from asset sales would be retained by the Company. Additional proceeds are then paid to JANA, Vicis and LSP as provided in the promissory notes. After these promissory note prepayments are made, proceeds up to $20,000,000 are split 50% to the Company and 50% to be paid pro-rata to these three lenders. Thereafter, proceeds are split 25% to the Company and 75% to the lenders. As of December 31, 2011, the Company owes these lenders $833,000 before additional proceeds are split between the Company and the lenders.

All of the outstanding long-term obligations described above mature on April 1, 2012. See “Note 2 – Management’s Plan” for additional discussion regarding the outstanding debt obligations.

Table of Contents

Note 8 – Stockholders’ Deficit

General

On October 14, 2009, the Company’s shareholders approved an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of the Company’s common stock to 300,000,000, $0.001 par value per share, from 200,000,000, $0.001 par value per share.

Warrants

The following represents warrants outstanding:

Exercise Price		Granted	Expiration	December 31, 2011		March 31, 2011
$	0.13	March 2011	March 2016		500,000		500,000
$	0.40	April 2010	April 2015		500,000		500,000
$	0.41	April 2009	April 2014		52,800		52,800
$	0.50	various	May 2011		-		2,301,744
$	0.50	May 2004	March 2014		1,070,796		1,070,796
$	0.75	June 2008	June 2015		490,000		490,000
$	0.95	November 2009	May 2015		7,135,713		7,135,713
					9,749,309		12,051,053

The outstanding warrants have no voting rights and provide the holder with the right to convert one warrant for one share of the Company’s common stock at the stated exercise price. The majority of the outstanding warrants have a cashless exercise feature.

The 7,135,713 warrants issued in November 2009 in conjunction with the equity financing transaction did not meet all of the criteria for equity classification. As a result, on November 17, 2009, the Company recorded the warrants in accordance with ASC Topic 815-40, “Derivatives and Hedging”, as a warrant liability at their then fair value of $2,478,000. The Company will mark the warrant liability to market at the end of each period until the Company complies with the requirements of equity classification of the warrant, at which time the warrant liability will be reclassified to equity. As a result, the Company recorded other income from the change in the fair value of these warrants of $14,000 and $500,000 for the three month periods ended December 31, 2011 and 2010, respectively, and $271,000 and $500,000 for the nine month periods ended December 31, 2011 and 2010, respectively.

The fair value of warrant liability was calculated under the Black-Scholes pricing model using the Company’s stock price on the date of the warrant grant, the warrant exercise price, the Company’s expected volatility, and the risk free interest rate matched to the warrants’ expected life. The Company does not anticipate paying dividends during the term of the warrants. The Company uses historical data to estimate volatility assumptions used in the valuation model. The expected term of warrants is equal to the contract life. The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the time of grant.

The specific assumptions used to determine the fair value of the warrants are as follows:

Weighted-average	December 31, 2011			March 31, 2011			November 17, 2009
Expected volatility		116	%		99	%		86	%
Expected dividend yields		0	%		0	%		0	%
Expected terms (in years)		3.4			4.1			5.5
Risk-free interest rate		0.48	%		1.80	%		2.19	%

Table of Contents

On April 23, 2010 and in conjunction with the HD Smith line of credit agreement (see “Note 3 – Discontinued Operations”), the Company granted HD Smith 500,000 warrants to purchase common stock at an exercise price of $0.40 per share. The warrants were to expire in April 2015. The Company also granted HD Smith an additional 500,000 warrants to purchase common stock. Consistent with the terms of the agreement, these warrants vested on March 31, 2011 because the value of the borrowing base supporting the line of credit did not exceed certain thresholds. The exercise price of $0.13 was computed consistent with the terms of the agreement as the lower of $0.40 and the preceding 10-day average of the closing prices per shares on March 31, 2011. The warrants were to expire in March 2016.

The fair value of the initial 500,000 warrants issued to HD Smith was estimated using the Black-Scholes pricing model and was determined to be $260,000. This amount was recorded as a debt discount and will be amortized over the term of the H.D. Smith line of credit. The assumptions used in the fair value calculation were as follows: risk free interest rate of 2.6%, expected dividend yield of 0%, expected volatility of 86%, and expected life of 5 years.

The fair value of the 500,000 warrants issued to HD Smith that vested on March 31, 2011 was estimated using the Black-Scholes pricing model and was determined to be $273,000. This amount was recorded as a debt discount and will be amortized over the term of the HD Smith line of credit. The assumptions used in the fair value calculation were as follows: risk free interest rate of 3.0%, expected dividend yield of 0%, expected volatility of 87%, and expected life of 6 years. Because the vesting of these warrants was contingent on a future event, the fair value of the warrants was originally classified as a liability until they vested on March 31, 2011, at which time they were reclassified to permanent equity as all the criteria for equity treatment were met at that point in time. Prior to the reclassification to permanent equity, the fair value of the liability was adjusted on a quarterly basis. For the three month and nine month periods ended December 31, 2010, the Company recorded $41,000 and $178,000, respectively, of other income, and these amounts represent the change in the fair value of the warrant liability during the year.

As discussed in “Note 3 – Discontinued Operations” and consistent with the Secured Creditor Assignment and Release Agreement dated December 6, 2011, all of the HD Smith warrants to purchase outstanding common stock were terminated on February 17, 2012 in conjunction with the closing of the sale of the Pharmacy assets.

No warrants were exercised during the three and nine month periods ended December 31, 2011 and 2010.

Note 9 — Contingencies

As a health care provider, the Company is subject to extensive federal and state government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, billing, documenting and other practices of health care companies are all subject to government scrutiny. To ensure compliance with Medicare and other regulations, audits may be conducted, with requests for patient records and other documents to support claims submitted for payment of services rendered to customers, beneficiaries of the government programs. Violations of federal and state regulations can result in severe criminal, civil and administrative penalties and sanctions, including disqualification from Medicare and other reimbursement programs.

The Company is subject to various legal proceedings and claims which arise in the ordinary course of business. The Company does not believe that the resolution of such actions will materially affect the Company’s business, results of operations or financial condition.

As previously disclosed, the Company was served with a complaint filed in the Marin County Superior Court of the State of California styled Douglas et al. vs. Arcadia Health Services, Inc., Case No. CIV 1102982 on June 20, 2011. The complaint is brought as a purported class action on behalf of California employees of Arcadia Health Services, Inc. (“AHSI”), an indirect wholly-owned subsidiary of the Company. The complaint alleges that (a) AHSI failed to properly compensate the plaintiff and purported class members for meal period and rest breaks under Sections 226.7 and 512 of the California Labor Code, (b) AHSI failed to pay continuing wages under California Labor Code Section 203, (c) AHSI failed to pay overtime compensation in accordance with California Labor Code Section 1194, and (d) that the foregoing allegations also constitute a violation of California Business and Professional Code Section 17200 (the “Lawsuit”). The plaintiff seeks to represent two classes of claimants, one representing claimants under the California Labor Code claims set forth in (a) through (c) above and another representing claimants under Section 17200 under the California Business and Professional Code. On July 18, 2011, AHSI filed an answer in the Marin County Superior Court denying all of the allegations in the complaint. On July 19, 2011, AHSI filed a petition to remove the case to federal court. The Lawsuit has been removed to federal court and is now pending in the United States District Court for the Northern District of California (the “District Court”).

On November 8, 2011, AHSI entered into a Settlement Agreement and General Release (the “Agreement” or “Settlement”) with Ruth L. Douglas (“Douglas”) individually and on behalf of others similarly situated (the “Class”) providing for both the settlement of the Lawsuit as set forth below. On January 17, 2012, the District Court entered an order (i) giving preliminary approval to the Settlement, (ii) conditionally certifying a class for settlement purposes consisting of any person employed by AHSI between June 15, 2007 and January 17, 2012, (iii) directing that notice of the Settlement and preliminary approval be provided to the putative class members and (iv) setting a hearing to consider final approval of the Settlement for April 17, 2012. The Agreement provides for, among other things, the (1) dismissal by Douglas and qualified members of the Class for asserted claims in the Lawsuit; (2) agreement to amend the Complaint to add the additional claims for relief of alleged damages under California Labor Code section 226 and alleged civil penalties under California Labor Code section 2699; and (3) a complete release of AHSI, Arcadia Services, Inc., RKDA, Inc and the Company from any and all claims, debts, liabilities, demands, obligations, guarantees, costs, expenses, attorneys' fees, penalties, damages, restitution, injunctive relief, or a remedy of any other type which are based on, arise out of, or are related to the causes of action of the Lawsuit, including but not limited to, claims made pursuant to the California Labor Code for failure to pay overtime compensation, failure to provide adequate meal periods and/or rest periods, failure to provide accurate wage statements, and failure to pay final wages in a timely fashion; and claims under California Business and Professions Code.

Table of Contents

The Company denies the allegations in the Lawsuit and further contends that the action may not properly be maintained as a class action. AHSI has entered into the Settlement to avoid the time, expense and the disruption of litigation and the risk of an adverse determination.

Pursuant to the Agreement, AHSI has agreed to pay a total sum of $623,000 (“Settlement Payment”), which shall be funded as follows: (1) $23,000 was paid following the execution of the Agreement; (2) $150,000 shall be paid within five business days of the Effective Date, as set forth below, into a to-be-established escrow interest-bearing account; (3) $225,000 shall be paid into the interest-bearing escrow account within 8 months of the Effective Date; and (4) $225,000 shall be paid into the interest-bearing escrow account within 14 months of the Effective Date. Funding of the Settlement Payment is solely the obligation of AHSI.

The Effective Date of the Settlement (“Effective Date”) is the date upon which: (a) the Settlement is finally approved substantially in accordance with the terms of this Settlement; and (b) the Court’s entry of Judgment and Dismissal of the Lawsuit (“Judgment”), substantially in accordance with the terms of this Settlement, become final. For purposes of defining the Effective Date, the date upon which the Settlement and Judgment become final is the last date of (a) final approval by the Court if there are no objections made and no further objections can be made; (b) if there are objections to the Settlement which are not withdrawn, and if no appeal, review or writ is sought from the Judgment, the day after the period for appeal has expired; or (c) if an appeal, review or writ is sought from the Judgment, the day after the Judgment is affirmed or the appeal, review or writ is dismissed or denied and the Judgment is no longer subject to further judicial review.

The Company recorded the full amount of the Settlement Payment of $623,000 as a selling and administrative expense during the three month period ended September 30, 2011. The Company made the initial payment of $23,000 during the three month period ended December 31, 2011. As of December 31, 2011, the remaining liability of $600,000 is included in “Accrued Expenses – Other” on the consolidated balance sheet.

Table of Contents

Note 10 – Stock-Based Compensation

On August 18, 2006, the Board of Directors unanimously approved the Arcadia Resources, Inc. 2006 Equity Incentive Plan (the “2006 Plan”), which was subsequently approved by the stockholders on September 26, 2006. The 2006 Plan provides for grants of incentive stock options, non-qualified stock options, stock appreciation rights and restricted shares (collectively “Awards”). The 2006 Plan will terminate and no more Awards will be granted after August 2, 2016, unless terminated by the Board of Directors sooner. The termination of the 2006 Plan will not affect previously granted Awards. All non-employee directors, executive officers and employees of the Company and its subsidiaries are eligible to receive Awards under the 2006 Plan.

On January 27, 2009, the Board of Directors approved and adopted the Second Amendment (the "Amendment") to the 2006 Plan, and the Amendment was approved by the stockholders on October 14, 2009. The Amendment increased the number of shares available to be issued under the Plan to 5% of the Company's authorized shares of common stock, or 15 million shares.

As of December 31, 2011, approximately 4.8 million shares were available for grant under the amended 2006 Plan.

Following are the specific valuation assumptions used for each respective period:

Three Month Period

Ended December 31,

Nine Month Period

Ended December 31,

Weighted-average

2011

2010

2011

2010

Expected volatility

N/A

Expected dividend yields

N/A

Expected terms (in years)

N/A

Risk-free interest rate

N/A

2.15

Stock option activity for the nine month period ended December 31, 2011 is summarized below:

Options	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value (thousands)
Outstanding at April 1, 2011		8,926,837		$	0.60
Forfeited or expired		(753,415	)		0.64
Outstanding at December 31, 2011		8,173,422		$	0.60		4.5	$	-
Exercisable at December 31, 2011		8,048,172		$	0.60		4.5	$	-

Table of Contents

The following table summarizes information about stock options outstanding at December 31, 2011:

	Options Outstanding						Options Exercisable
			Weighted
			Average		Weighted				Weighted
			Remaining		Average				Average
	Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life		Price		Exercisable		Price
$0.18 -$0.42		3,996,734		4.8	$	0.38		3,871,484	$	0.38
$0.43 - $0.72		3,100,501		3.6		0.72		3,100,501		0.72
$0.73 - $1.07		756,647		3.9		0.79		756,647		0.79
$1.08 - $1.50		201,927		2.4		1.29		201,927		1.29
$1.51 - $2.25		43,000		1.3		2.22		43,000		2.22
$2.92		74,613		1.6		2.92		74,613		2.92
Outstanding at December 31, 2011		8,173,422			$	0.60		8,048,172	$	0.60

No stock options were granted during the nine month periods ended December 31, 2011 and 2010. No stock options were exercised during the nine month period ended December 31, 2011. 3,750 stock options were exercised during the nine month period ended December 31, 2010.

The Company recognized $9,000 and $303,000 in stock-based compensation expense from all operations relating to stock options during the three month periods ended December 31, 2011 and 2010, respectively, and $168,000 and $785,000 for the nine month periods ended December 31, 2011 and 2010, respectively.

As of December 31, 2011, total unrecognized stock-based compensation expense related to stock options was $9,000, which is expected to be expensed through November 2012.

Restricted Stock

Restricted stock is measured at fair value on the date of the grant, based on the number of shares granted and the quoted price of the Company’s common stock. The value is recognized as compensation expense ratably over the corresponding employee’s specified service period. Restricted stock vests upon the employees’ fulfillment of specified performance and service-based conditions.

The following table summarizes the activity for restricted stock awards during the nine month period ended December 31, 2011:

				Grant Date
				Fair Value
	Shares			per Share
Unvested at April 1, 2011		145,467		$	0.66
Vested		(137,500	)		0.66
Forfeited		(7,967	)		-
Unvested at December 31, 2011		-		$	0.00

During the three month periods ended December 31, 2011 and 2010, the Company recognized $17,000 and $271,000, respectively, of stock-based compensation expense from all operations related to restricted stock. During the nine month periods ended December 31, 2011 and 2010, the Company recognized $75,000 and $271,000, respectively, of stock-based compensation expense from all operations related to restricted stock.

During the nine month periods ended December 31, 2011 and 2010, the total fair value of restricted stock vested was $91,000, and $239,000, respectively.

Table of Contents

Note 11 – Income Taxes

The Company incurred state and local tax expense of $19,000 and $30,000 during the three month periods ended December 31, 2011 and 2010, respectively, and $60,000 and $102,000 during the nine month periods ended December 31, 2011 and 2010.

ASC Topic 740 requires that a valuation allowance be established when it is more likely than not that all or a portion of deferred income tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including a company’s performance, the market environment in which the company operates, the length of carryback and carryforward periods, and expectation of future profits. The relevant guidance further states, that forming a conclusion that a valuation allowance is not needed is difficult when there is negative evidence such as the cumulative losses in recent years. Therefore, cumulative losses weigh heavily in the overall assessment. The Company will continue to provide a full valuation allowance on future tax benefits until it can sustain a level of profitability that demonstrates its ability to utilize the assets, or other significant positive evidence arises that suggests the Company’s ability to utilize such assets.

Note 12 – Related Party Transactions

On December 31, 2011, the Company had an outstanding balance of $20,905,000 related to a note payable with JANA dated March 25, 2009. JANA held approximately 13% of the outstanding shares of Company common stock on December 31, 2011. The Company incurred interest expense relating to the debt due JANA in the amounts of $514,000 and $466,000 during the three month periods ended December 31, 2011 and 2010, respectively, and $1,499,000 and $1,300,000 for the nine month periods ended December 31, 2011 and 2010, respectively. See “Note 7 – Long-term Obligations” for additional information pertaining to the balances of these debt instruments.

On December 31, 2011, the Company had an outstanding balance of $7,735,000 related to a note payable with Vicis Capital Master Fund dated March 25, 2009. Vicis held approximately 12% of the outstanding shares of Company common stock on December 31, 2011. The Company incurred interest expense relating to the debt in the amount of $190,000 and $172,000 during the three month periods ended December 31, 2011 and 2010, respectively, and $555,000 and $503,000 for the nine month periods ended December 31, 2011 and 2010, respectively. See “Note 7 – Long-term Obligations” for additional information pertaining to the balances of this debt instrument.

Prior to April 4, 2011, the Company’s Chief Operating Officer had a beneficial ownership interest in an affiliated agency and thereby had an interest in the affiliate’s transactions with the Company, including the payments of commissions to the affiliate based on a specified percentage of gross margin. The terms of these transactions were consistent with the affiliate agreement, which was entered into on August 13, 2006. The affiliate is responsible to pay its selling, general and administrative expenses. Commissions totaled $194,000 and $598,000 for the three and nine month periods ended December 31, 2010, respectively. On April 4, 2011, the Company finalized the purchase of substantially all of the assets of the affiliate as required by the affiliate agreement for total consideration of $890,000 pursuant to the purchase price formula contained in the agreement. Of the purchase price, $297,000 was paid in cash at the closing, and the Company entered into a promissory note for the remaining $593,000. The Company incurred interest expense relating to the debt in the amount of $15,000 and $45,000 during the three and nine month periods ended December 31, 2011, respectively.

See “Note 7 – Long-Term Obligations” for additional information pertaining to the balances of these debt instruments.

Table of Contents

ITEM 2. Management’s Discussion And Analysis Of Financial Condition And Results Of Operations

The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three and nine month periods ended December 31, 2011 and 2010. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, the consolidated financial statements and notes and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended March 31, 2011 filed with the SEC on June 28, 2011, which is incorporated herein by this reference.

Cautionary Statement Concerning Forward-Looking Statements

The MD&A should be read in conjunction with the other sections of this report on Form 10-Q, including the consolidated financial statements and notes thereto beginning on page 2 of this Report. Historical results set forth in the financial statements beginning on page 2 and this section should not be taken as indicative of our future operations.

We caution you that statements contained in this report (including our documents incorporated herein by reference) include forward-looking statements. The Company claims all safe harbor and other legal protections provided to it by law for all of its forward-looking statements. Forward-looking statements involve known and unknown risks, assumptions, uncertainties and other factors about our Company, which could cause actual financial or operating results, performances or achievements expressed or implied by such forward-looking statements not to occur or be realized. Such forward-looking statements generally are based on our reasonable estimates of future results, performances or achievements, predicated upon current conditions and the most recent results of the companies involved and their respective industries. Forward-looking statements are also based on economic and market factors and the industry in which we do business, among other things. Forward-looking statements are not guaranties of future performance. Forward-looking statements may be identified by the use of forward-looking terminology such as “may,” “can,” “will,” “could,” “should,” “project,” “expect,” “plan,” “predict,” “believe,” “estimate,” “aim,” “anticipate,” “intend,” “continue,” “potential,” “opportunity” or similar terms, variations of those terms or the negative of those terms or other variations of those terms or comparable words or expressions.

Unless otherwise provided, “Arcadia,” “we,” “us,” “our,” and the “Company” refer to Arcadia Resources, Inc. and its wholly-owned subsidiaries.

Actual events and results may differ materially from those expressed or forecasted in forward-looking statements due to a number of factors. Important factors that could cause actual results to differ materially include, but are not limited to (1) our ability to compete with our competitors; (2) our ability to obtain additional debt or equity financing, if necessary, and/or to restructure existing indebtedness, which may be difficult due to our history of operating losses and negative cash flows; (3) the ability of our affiliated agencies to effectively market and sell our services and products; (4) our ability to procure product inventory for resale; (5) our ability to recruit and retain temporary workers for placement with our customers; (6) the timely collection of our accounts receivable; (7) our ability to attract and retain key management employees; (8) our ability to timely develop new services and products and enhance existing services and products; (9) our ability to execute and implement our growth strategy; (10) the impact of governmental regulations; (11) marketing risks; (12) our ability to adapt to economic, political and regulatory conditions affecting the health care industry; (13) our ability to successfully integrate acquisitions; (14) the ability of our management team to successfully pursue our business plan; (15) other unforeseen events that may impact our business; and (16) the risks, uncertainties and other factors described in Part II, Item 1A of this Report which are incorporated herein by this reference.

Table of Contents

Overview

Critical Accounting Policies

See Part II, Item 7 – Critical Accounting Policies, our consolidated financial statements and related notes in Part IV, Item 15 of our Annual Report on Form 10-K for the year ended March 31, 2011 filed with the SEC on June 28, 2011 for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties.

Three Month Period Ended December 31, 2011 Compared to the Three Month Period Ended December 31, 2010

Results of Continuing Operations (in thousands, except per share amounts)

	Three Month Period
	Ended December 31,
	2011			2010
Revenues, net	$	20,644		$	21,139
Cost of revenues		14,541			14,733
Gross profit		6,103			6,406

Selling, general and administrative		6,295			6,727
Depreciation and amortization		157			254
Goodwill and intangible asset impairment		7,786			-
Total operating expenses		14,238			6,981

Operating loss		(8,135	)		(575	)

Other expenses:
Interest expense, net		950			872
Change in fair value of warrant liability		(14	)		(541	)
Total other expenses		936			331

Net loss before income tax expense		(9,071	)		(906	)
Income tax expense		19			30
Net loss from continuing operations	$	(9,090	)	$	(936	)
Weighted average number of shares — basic and diluted		193,341			187,309
Net loss from continuing operations per share — basic and diluted	$	(0.05	)	$	-

Table of Contents

Revenues, Cost of Revenues and Gross Profits

The following table summarizes the revenues by type for the three month periods ended December 31, (in thousands):

	2011		% of Total Revenue			2010		% of Total Revenue			$ Increase/ (Decrease)			% Increase/ (Decrease)

Home care	$	17,546		85.0	%	$	16,971		80.4	%	$	575			3.4	%
Per diem medical staffing		2,897		14.0	%		2,831		13.4	%		66			2.3	%
Travel staffing		201		1.0	%		1,337		6.2	%		(1,136	)		-85.0	%
	$	20,644		100.0	%	$	21,139		100.0	%	$	(495	)		-2.3	%

Revenue comes from two business lines, Home Care and Medical Staffing. Medical Staffing consists of both per diem staffing as well as travel nursing and allied health staffing.

For the quarter ended December 31, 2011, Home Care revenue as a percentage of total revenue increased to 85.0% as compared with 80.4% for the prior year period. Home Care revenues increased by $575,000, or 3.4%, to $17,546,000 from $16,971,000 compared to the prior year quarter.

Total Medical Staffing revenue declined 25.7% compared to the prior year quarter to $3,098,000 from $4,168,000. Per diem medical staffing increased 2.3% over the prior year quarter, while travel nursing and allied health medical staffing decreased 85.0% over the prior year quarter. While overall demand for temporary medical staffing remains depressed driven by low patient censuses, the return of retired or part-time staff to full time status and the increases in overtime accepted by permanent staff at many facilities, there has been some improvement in market conditions for temporary medical staffing. In February 2011, the Company was notified that it was not awarded a new contract to provide travel nurses to the North Carolina Department of Corrections, which accounted for approximately $4,100,000 in revenue during fiscal 2011, because of lower price proposals received from other vendors. The Company’s appeal of this decision was denied in June 2011.

The business operates independently and through a network of affiliated agencies (“Affiliates”) throughout the United States. These affiliated agencies are independently-owned, owner-managed businesses, which have been contracted by the Company to sell services under the Arcadia name. The affiliated agency’s commission is based on a percentage of gross profit (see additional discussion in the “Selling, General and Administrative” section). Revenue generated from the Affiliate locations was $12,986,000 for the three month period ended December 31, 2011 compared to $14,113,000 for the prior year quarter. This $1,127,000, or 8.0%, decrease in revenue was primarily driven by the conversion of the travel staffing Affiliate to a Company Owned location in April 2011. The Company-Owned locations revenue increased by $632,000, or 9.0%, to $7,658,000 during the fiscal third quarter 2012 compared to the prior year quarter. The Affiliate locations accounted for 62.9% of total Services segment revenue during the fiscal third quarter 2012, and this percentage is down slightly from 66.8% for the prior year quarter.

Gross margin was 29.6% for the fiscal third quarter 2012 compared to 30.3% for the prior year quarter. Gross margin was positively affected by the shift in mix towards higher margin Home Care business. However, this improvement was offset by reimbursement rate reductions in certain state Medicaid programs, an increase in workers compensation costs effective with the new insurance policy period beginning in October 2011 and higher unemployment taxes.

Selling, General and Administrative

Total selling, general and administrative expense decreased by $432,000, or 6.4%, to $6,295,000 during the three month period ended December 31, 2011 compared to the prior year period. This decrease was primarily due to decreases in equity compensation and commissions paid to Affiliates. Equity compensation continues to decrease as stock option and restricted stock grants made in prior periods at higher values become fully vested. The decrease in Affiliate commissions was consistent with the decrease in revenue generated by the Affiliate locations (see revenue discussion above).

Table of Contents

Depreciation and Amortization

The following table summarizes depreciation and amortization expense for the three month periods ended December 31 (in thousands):

	2011		2010		$ Increase/ (Decrease)			% Increase/ (Decrease)
Depreciation and amortization of property and equipment	$	28	$	111	$	(83	)		-74.8	%
Amortization of acquired intangible assets		129		143		(14	)		-9.8	%
Depreciation and amortization	$	157	$	254	$	(97	)		-38.2	%

Depreciation and amortization of property and equipment decreased by $83,000, or 74.8%, during the three month period ended December 31, 2011 compared to the prior year period. The decrease was due to certain computer equipment and software becoming fully-depreciated over the last several quarters.

Amortization of acquired intangible assets decreased by $14,000, or 9.8%, during fiscal third quarter 2012 compared to the prior year quarter. The decrease reflects a decrease in the amortization expense associated with customer relationships. The amortization expense is adjusted based on economic benefit generated by the specific intangible asset.

Goodwill and Intangible Asset Impairment

The following table summarizes the goodwill and intangible asset impairment expense for the three month periods ended December 31, (in thousands):

	2011		2010
Goodwill impairment	$	1,076	$	-
Trade name impairment		5,518		-
Customer relationships impairment		1,192		-
	$	7,786	$	-

Based on the decline in the Company’s market capitalization and the near term cash flow projections, management determined that it was appropriate to perform an impairment assessment of goodwill and the amortizable intangible assets as of December 31, 2011. Management has been in discussions with various parties regarding the possible sale of the Home Care/Medical Staffing business for the last several quarters. Based on these discussions and on the near-term cash flow projections, management determined that a complete impairment of the goodwill and acquired intangible assets was appropriate. As such, the Company recognized $1,076,000 and $6,710,000 of goodwill and intangible asset impairment, respectively.

Interest Expense and Income

The following table summarizes interest expense and income for the three month periods ended December 31, (in thousands):

	2011			2010			$ Increase/ (Decrease)		% Increase/ (Decrease)
Interest expense	$	951		$	875		$	76		8.7	%
Interest income		(1	)		(3	)		2		-66.7	%
	$	950		$	872		$	78		8.9	%

Table of Contents

Interest expense for fiscal third quarter 2012 was $951,000, which represents a $76,000, or 8.7%, increase compared to the prior year quarter expense of $875,000. Total interest expense includes the amortization of deferred financing costs of $52,000 for both fiscal third quarter 2012 and 2011. Additionally, interest expense includes non-cash interest of $736,000 and $667,000 that was added to the principal balance of the outstanding debt for fiscal third quarter 2012 and 2011, respectively. The increase was primarily due to the increase in the amounts due to Comerica Bank under the line of credit agreement as well as the additional amount due to unsecured lenders as the quarterly interest expense was added to the principal balance of the outstanding debt.

Change in Fair Value of Warrant Liability

The 7,135,713 warrants issued in November 2009 in conjunction with the equity financing transaction and an additional 500,000 warrants issued in conjunction with the H.D. Smith debt financing are recorded as a liability at fair value with subsequent changes in fair value recorded in earnings. The fair value of the warrants is determined using the Black-Scholes pricing model and is affected by changes in inputs to that model, including: our stock price, expected stock price volatility, and contractual terms. To the extent that the fair value of the warrant liability increases or decreases, the Company records a loss or gain in the statement of operations. The total gain on the change in fair value of the warrant liability was $14,000 and $541,000 during fiscal third quarter 2012 and 2011, respectively, was primarily due to the changes in our stock price.

Income Taxes

Income tax expense was $19,000 for the three month period ended December 31, 2011 compared to $30,000 for the same period a year ago.

Due to the Company’s losses in recent years, it has paid nominal federal income taxes. For federal income tax purposes, the Company had significant permanent and timing differences between book income and taxable income resulting in combined net deferred tax asset balance to be utilized by the Company for which an offsetting valuation allowance has been established for the entire amount. The Company has a net operation loss carry-forward for tax purposes totaling $78.4 million that expires at various dates through 2031. Internal Revenue Code Section 382 rules limit the utilization of certain of these net operation loss carry-forwards upon a change of control of the Company. It has been determined that a change in control took place at the time of the reverse merger in 2004, and as such, the utilization of $700,000 of the net operating loss carry-forwards will be subject to severe limitations in future periods.

Table of Contents

Earnings (Loss) from Discontinued Operations

The components of the earnings/(loss) from discontinued operations by segment are presented below (in thousands):

	Three Month Period Ended December 31, 2011
	Services		Pharmacy			Total

Revenues, net	$	-	$	4,316		$	4,316
Cost of revenue		-		3,764			3,764
Gross profit		-		552			552

Selling, general and administrative		-		1,203			1,203
Depreciation and amortization		-		71			71
Total operating expenses		-		1,274			1,274

Interest expense		-		78			78

Loss from operations		-		(800	)		(800	)
Net gain on disposal		114		-			114

Earnings (loss) from discontinued operations	$	114	$	(800	)	$	(686	)

	Three Month Period Ended December 31, 2010
	Services			Pharmacy			Catalog			Total

Revenues, net	$	-		$	5,033		$	-		$	5,033
Cost of revenue		-			4,219			-			4,219
Gross profit		-			814			-			814

Selling, general and administrative		7			2,177			29			2,213
Depreciation and amortization		-			80			-			80
Total operating expenses		7			2,257			29			2,293

Interest expense		-			131			-			131

Loss from operations		(7	)		(1,574	)		(29	)		(1,610	)
Net gain (loss) on disposal		292			-			(64	)		228

Earnings (loss) from discontinued operations	$	285		$	(1,574	)	$	(93	)	$	(1,382	)

Pharmacy Segment

On December 6, 2011, the Company executed an Asset Purchase Agreement with Medication Adherence Solutions, LLC to sell substantially all of the assets of its Pharmacy segment, which transaction was closed on February 17, 2012. See the discussion of the sale of the Pharmacy segment in “Note 3 – Discontinued Operations”.

Table of Contents

Services Segment

HHE Segment

As of May 2009, the Company had sold all of its HHE operations.

Catalog Segment

Prior to their actual disposal, the assets and liabilities associated with these discontinued business operations have been classified as assets and liabilities of discontinued operations in the accompanying consolidated balance sheets. The results of the above businesses are reported in discontinued operations in the accompanying consolidated statements of operations, and the prior period consolidated statements of operations have been recast to conform to this presentation. The discontinued operations do not reflect the costs of certain services provided to these operations by the Company. Such costs, which were not allocated by the Company to the various operations, included internal employee costs associated with administrative functions, including accounting, information technology, human resources, compliance and contracting as well as external costs for legal fees, insurance, audit fees, payroll processing, and various public-company expenses. The Company uses a centralized approach to cash management and financing of its operations, and, accordingly, debt and the related interest expense were also not allocated specifically to these operations. The consolidated statements of cash flows do not separately report the cash flows of the discontinued operations.

Table of Contents

Nine Month Period Ended December 31, 2011 Compared to the Nine Month Period Ended December 31, 2010

Results of Continuing Operations (in thousands, except per share amounts)

	Nine Month Period
	Ended December 31,
	2011			2010
Revenues, net	$	61,504		$	62,434
Cost of revenues		43,291			43,646
Gross profit		18,213			18,788

Selling, general and administrative		20,819			21,350
Depreciation and amortization		542			752
Goodwill and intangible asset impairment		7,786			-
Total operating expenses		29,147			22,102

Operating loss		(10,934	)		(3,314	)

Other expenses:
Interest expense, net		2,762			2,497
Change in fair value of warrant liability		(271	)		(678	)
Total other expenses		2,491			1,819

Net loss before income tax expense		(13,425	)		(5,133	)
Income tax expense		60			102
Net loss from continuing operations	$	(13,485	)	$	(5,235	)
Weighted average number of shares — basic and diluted		193,303			180,627
Net loss from continuing operations per share — basic and diluted	$	(0.07	)	$	(0.03	)

Table of Contents

Revenues, Cost of Revenues and Gross Profits

The following table summarizes revenues by type for the nine month periods ended December 31, (in thousands):

	2011		% of Total Revenue			2010		% of Total Revenue			$ Increase/ (Decrease)			% Increase/ (Decrease)

Home care	$	51,946		84.5	%	$	50,189		80.5	%	$	1,757			3.5	%
Per diem medical staffing		8,654		14.0	%		8,142		13.0	%		512			6.3	%
Travel staffing		904		1.5	%		4,103		6.5	%		(3,199	)		-78.0	%
	$	61,504		100.0	%	$	62,434		100.0	%	$	(930	)		-1.5	%

Revenue comes from two business lines, Home Care and Medical Staffing. Medical Staffing consists of both per diem staffing as well as travel nursing and allied health staffing.

For the nine month period ended December 31, 2011, Home Care revenue as a percentage of total revenue increased to 84.5% as compared with 80.5% for the prior year period. Home Care revenues increased by $1,757,000, or 3.5%, to $51,946,000 from $50,189,000 compared to the prior year period.

Total Medical Staffing revenue declined 21.9% compared to the prior nine month period to $9,558,000 from $12,245,000. Per diem medical staffing increased 6.3% over the prior year period, while travel nursing and allied health medical staffing decreased 78.0% over the prior year period. While overall demand for temporary medical staffing remains depressed driven by low patient censuses, the return of retired or part-time staff to full time status and the increases in overtime accepted by permanent staff at many facilities, there has been some improvement in demand for temporary medical staffing. In February 2011, the Company was notified that it was not awarded a new contract to provide travel nurses to the North Carolina Department of Corrections, which accounted for approximately $4,100,000 in revenue during fiscal 2011, because of lower price proposals received from other vendors. The Company’s appeal of this decision was denied on June 3, 2011.

The business operates independently and through a network of affiliated agencies (“Affiliates”) throughout the United States. These affiliated agencies are independently-owned, owner-managed businesses, which have been contracted by the Company to sell services under the Arcadia name. The affiliated agency’s commission is based on a percentage of gross profit (see additional discussion in the “Selling, General and Administrative” section). Revenue generated from the Affiliate locations was $38,756,000 for the nine month period ended December 31, 2011 compared to $41,256,000 for the prior year period. This $2,500,000, or 6.1%, decrease in revenue was primarily driven by the conversion of the travel staffing Affiliate to a Company Owned location in April 2011. The Company-Owned locations revenue increased 7.4% to $22,748,000 during the nine month period ended December 31, 2011 compared to the prior year period. The Affiliate locations accounted for 63.0% of total revenue during the nine month period ended December 31, 2011, and this percentage is down from 66.1% for the prior year period.

Gross margin was 29.6% for the nine month period ended December 31, 2011, which represents a slight decrease from 30.1% for the prior year period. Gross margin was positively affected by the shift in mix towards higher margin Home Care business. However, this improvement was offset by reimbursement rate reductions in certain state Medicaid programs, an increase in workers compensation costs effective with the new insurance policy period beginning in October 2011, higher unemployment taxes and certain one-time costs.

Selling, General and Administrative

Total selling, general and administrative expense decreased by $531,000, or 2.5%, to $20,819,000 during the nine month period ended December 31, 2011 compared to the prior year period. The net decrease was primarily driven by decreases in equity compensation and Affiliate commissions offset by the $623,000 legal settlement recognized during the fiscal second quarter and certain professional fees associated with this dispute and with restructuring efforts. Equity compensation continues to decrease as stock option and restricted stock grants made in prior periods at higher values become fully vested. The decrease in Affiliate commissions was consistent with the decrease in revenue generated by the Affiliate locations (see revenue discussion above).

Table of Contents

Depreciation and Amortization

The following table summarizes depreciation and amortization expense for the nine month periods ended December 31, (in thousands):

	2011		2010		$ Increase/ (Decrease)			% Increase/ (Decrease)
Depreciation and amortization of property and equipment	$	154	$	323	$	(169	)		-52.3	%
Amortization of acquired intangible assets		388		429		(41	)		-9.6	%
Depreciation and amortization	$	542	$	752	$	(210	)		-27.9	%

Depreciation and amortization of property and equipment decreased by $169,000, or 52.3%, during the nine month period ended December 31, 2011 compared to the prior year period. The decrease was due to certain computer equipment and software becoming fully-depreciated over the last several quarters.

Amortization of acquired intangible assets decreased by $41,000, or 9.6%, during the nine month period ended December 31, 2011 compared to the prior year period. The decrease reflects a decrease in the amortization expense associated with customer relationships. The amortization expense is adjusted annually and attempts to match the expense to the economic benefit generated by the specific intangible asset.

Goodwill and Intangible Asset Impairment

The following table summarizes the goodwill and intangible asset impairment expense for the nine month periods ended December 31, (in thousands):

	2011		2010
Goodwill impairment	$	1,076	$	-
Trade name impairment		5,518	$	-
Customer relationships impairment		1,192		-
	$	7,786	$	-

Based on the decline in the Company’s market capitalization and the near term cash flow projections, management determined that it was appropriate to perform an impairment assessment of goodwill and the amortizable intangible assets as of December 31, 2011. Management has been in discussions with various parties regarding the possible sale of the Home Care/Medical Staffing business for the last several quarters. Based on these discussions and on the near-term cash flow projections, management determined that a complete impairment of the goodwill and acquired intangible assets was appropriate. As such, the Company recognized $1,076,000 and $6,710,000 of goodwill and intangible asset impairment, respectively.

Interest Expense and Income

The following table summarizes interest expense and income for the nine-month periods ended December 31, (in thousands):

	2011			2010			$ Increase/ (Decrease)		% Increase/ (Decrease)
Interest expense	$	2,765		$	2,504		$	261		10.4	%
Interest income		(3	)		(7	)		4		-57.1	%
	$	2,762		$	2,497		$	265		10.6	%

Table of Contents

Interest expense for the nine month period ended December 31, 2011 was $2,765,000, which represents a $261,000, or 10.4%, increase compared to the prior year period expense of $2,504,000. Total interest expense includes the amortization of deferred financing costs of $156,000 for both the nine month periods ended December 31, 2011 and 2010. Additionally, interest expense includes non-cash interest of $2,148,000 and $1,946,000 that was added to the principal balance of the outstanding debt for nine month periods ended December 31, 2011 and 2010, respectively. The increase was primarily due to the increase in the amounts due to Comerica Bank under the line of credit agreement executed in April 2010 as well as the additional amount due to unsecured lenders as the quarterly interest expense was added to the principal balance of the outstanding debt.

Change in Fair Value of Warrant Liability

The 7,135,713 warrants issued in November 2009 in conjunction with the equity financing transaction and an additional 500,000 warrants issued in conjunction with the H.D. Smith debt financing are recorded as a liability at fair value with subsequent changes in fair value recorded in earnings. The fair value of the warrants is determined using the Black-Scholes pricing model and is affected by changes in inputs to that model, including: our stock price, expected stock price volatility, and contractual terms. To the extent that the fair value of the warrant liability increases or decreases, the Company records a loss or gain in the statement of operations. The total gain on the change in fair value of the warrant liability was $271,000 and $678,000 during the nine month periods ended December 31, 2011 and 2010, respectively, was primarily due to the changes in our stock price.

Income Taxes

Income tax expense was $60,000 for the nine month period ended December 31, 2011 compared to $102,000 for the same period a year ago.

Table of Contents

Earnings (Loss) from Discontinued Operations

The following table summarizes the components of the earnings (loss) from discontinued operations for the nine month period ended December 31, (in thousands):

	Nine Month Period Ended December 31, 2011
	Services		Pharmacy			Total

Revenues, net	$	-	$	13,249		$	13,249
Cost of revenue		-		11,475			11,475
Gross profit		-		1,774			1,774

Selling, general and administrative		-		4,337			4,337
Depreciation and amortization		-		212			212
Total operating expenses		-		4,549			4,549

Interest expense		-		343			343

Loss from operations		-		(3,118	)		(3,118	)
Net gain on disposal		841		-			841

Earnings (loss) from discontinued operations	$	841	$	(3,118	)	$	(2,277	)

	Nine Month Period Ended December 31, 2010
	Services			Pharmacy			HHE		Catalog			Total

Revenues, net	$	-		$	14,998		$	-	$	660		$	15,658
Cost of revenue		-			12,759			-		397			13,156
Gross profit		-			2,239			-		263			2,502

Selling, general and administrative		7			6,868			-		374			7,249
Depreciation and amortization		-			217			-		-			217
Total operating expenses		7			7,085			-		374			7,466

Interest expense		-			330			-		-			330

Loss from operations		(7	)		(5,176	)		-		(111	)		(5,294	)
Net gain (loss) on disposal		683			-			655		(64	)		1,274

Earnings (loss) from discontinued operations	$	676		$	(5,176	)	$	655	$	(175	)	$	(4,020	)

Pharmacy Segment

Table of Contents

Services Segment

HHE Segment

On May 19, 2009, the Company entered into an Asset Purchase Agreement with Braden Partners, L.P. to sell the assets of its Midwest region of the Company’s HHE business. Total proceeds were $4,000,000, less fees of $150,000. $1,000,000 of the purchase price was held by the buyer to cover the Company’s contingent obligations. Subsequent to the transaction date, the buyer made certain claims, and in June 2010, the buyer and the Company received a final settlement payment of $500,000 to resolve these claims. This payment was recognized as an additional gain on the sale during the nine month period ended December 31, 2010.

As of May 2009, the Company had sold all of its HHE operations.

Catalog Segment

Prior to their actual disposal, the assets and liabilities associated with these discontinued business operations have been classified as assets and liabilities of discontinued operations in the accompanying consolidated balance sheets. The results of the above businesses are reported in discontinued operations in the accompanying consolidated statements of operations, and the prior period consolidated statements of operations have been recast to conform to this presentation. The discontinued operations do not reflect the costs of certain services provided to these operations by the Company. Such costs, which were not allocated by the Company to the various operations, included internal employee costs associated with administrative functions, including accounting, information technology, human resources, compliance and contracting as well as external costs for legal fees, insurance, audit fees, payroll processing, and various public-company expenses. The Company uses a centralized approach to cash management and financing of its operations, and, accordingly, debt and the related interest expense were also not allocated specifically to these operations. The consolidated statements of cash flows do not separately report the cash flows of the discontinued operations.

Table of Contents

Liquidity and Capital Resources

As a result of this transaction, the Company no longer operates the Pharmacy segment as of February 17, 2012. The Pharmacy segment was previously reported as a discontinued operation.

As a result of the above, the Company is continuing to pursue the sale of the Services business and is in on-going discussions with several parties regarding the potential sale.

While the Services segment is not in compliance with certain covenants under the Comerica Credit Line, the Comerica Debt has not been accelerated and Comerica continues to provide funding for Services segment operations. The Company anticipates that Comerica will continue to provide funding to the Services segment until the business is sold. However, at any time Comerica has the right to accelerate the maturity of the Comerica Debt and declare the outstanding principal amount to be immediately due and payable. In addition, the indebtedness under the Comerica Credit Line matures and becomes due and payable on April 1, 2012. For a further description of the status of the Comerica Credit Line, see “Note 6 – Line of Credit”.

For these reasons, investors are strongly discouraged from trading in the Company’s common stock because it is highly unlikely that there is any equity value related to the common shares.

The following summarizes the Company’s cash flows for the nine month periods ended December 31, (in thousands):

	2011			2010
Net cash used in operating activities	$	(5,814	)	$	(10,500	)
Net cash provided by investing activities		1,372			229
Net cash provided by financing activities		2,306			8,623
Net change in cash and cash equivalents		(2,136	)		(1,648	)
Cash and cash equivalents, end of period		-			3,796
Availability under line of credit agreements	$	-		$	609

At December 31, 2011, the Company had no cash or line of credit availability as compared to $4,405,000 at December 31, 2010. The maximum amount available under the line of credit agreement depends on the amount of eligible accounts receivable at any point in time, and the availability under the line of credit fluctuates based on working capital needs. As the Company continues to use cash, the availability continues to decline. Management is working closely with Comerica Bank to fund daily operations.

Table of Contents

Net cash used in operating activities was $5,814,000 for the nine month period ended December 31, 2011 compared to $10,500,000 for the same period of the prior year, which represents a change of $4,686,000. The majority of this change was driven by changes in working capital. The net change in operating assets and liabilities for the current period was negative $812,000 compared to negative $4,284,000 in the prior year period, which represents a difference of $3,472,000.

Cash provided by investing activities was $1,372,000 for the nine month period ended December 31, 2011. This included the release of $1,000,000 of cash that was previously restricted per the Company’s agreements with Comerica Bank as well as $841,000 of additional cash payments received relating to prior year business divestitures. These proceeds were offset by $371,000 in cash payments for business acquisitions, primarily the Bestaff acquisition, and $98,000 in capital expenditures.

Cash provided by financing activities was $2,306,000 for the nine month period ended December 31, 2011. Cash provided by financing activities was $8,623,000 for the nine month period ended December 31, 2010. During the first nine months of fiscal 2012, the Company drew $2,326,000 from the Comerica line of credit, and paid $20,000 on capital lease obligations. During the first nine months of fiscal 2011, the Company drew $4,500,000 from the HD Smith line of credit, which was originally entered into in April 2010, and $447,000 from the Comerica Bank line of credit. Additionally, the Company generated $4,476,000 of cash through the sale of common stock, net of $536,000 of cash fees. During this same period, the Company paid off a note payable due to AmerisourceBergen Drug Corporation of $750,000 as well as $52,000 in various capital lease obligations.

As of December 31, 2011, the Company had the following debt obligations:

Lender	Description	Maturity	Balance

JANA Master Fund, Ltd.	note payable	April 1, 2012	$	20,905
Vicis Capital Master Fund	note payable	April 1, 2012		7,735
Comerica Bank (Home Care/Medical Staffing segment)	line of credit	April 1, 2012		9,456
HD Smith, net of unamortized debt discount (Pharmacy segment)	line of credit	April 23, 2013		4,521
LSP Partners, LP	note payable	April 1, 2012		1,315
BestCare Travel Staffing, LLC	note payable	April 1, 2012		593
Various	capital leases	various		6
Total			$	44,531

JANA and Vicis own approximately 13% and 12% of the Company’s outstanding common stock, respectively. The debt agreements with JANA, Vicis and LSP Partners require the lenders’ consent for debt transactions which are senior or pari passu to the debt due them. Additionally, the lenders also require consent for equity transactions.

The Comerica Bank line of credit provides working capital for the Services segment. The agreement includes certain financial covenants. These covenants are specific to Arcadia Services, Inc., a wholly-owned subsidiary of the Company, which is the legal entity that operates the Company’s Services segment. On October 31, 2010, the Company and the bank entered into an amendment and waiver agreement. The amendment reduced the revolving credit commitment amount from $14 million to $11 million and extended the maturity date to April 1, 2012. Subsequent to this amendment, the following financial covenants apply: tangible effective net worth of $750,000 as of December 31, 2010 and gradually increasing on a quarterly basis to $1.25 million by March 31, 2012; minimum quarterly net income of $400,000; and, minimum subordination of indebtedness to Arcadia Resources, Inc. of $9.15 million. Finally, the amendment increased the required restricted cash balance from $500,000 to $1,000,000. In the event of default of any one of the financial covenants, the bank may declare all outstanding indebtedness due and payable, and the bank shall not be obligated to make any further advances to Arcadia Services, Inc.

On a monthly basis, the Company submits Arcadia Services, Inc. (“ASI”) financial information to Comerica. On September 13, 2011, ASI and its wholly-owned subsidiaries (“Services Borrowers”) received a letter from Comerica stating that the Services Borrowers failed to comply with certain covenants under the credit agreement because as of July 31, 2011, ASI failed to be in compliance with the subordinated debt covenant. Because of the events described in the notice letter, Comerica informed the Services Borrowers that Comerica has no obligation to make further advances under the credit facility and that future advances shall be subject to the sole discretion of Comerica. Comerica has not sought to accelerate the repayment of the indebtedness or to foreclose on any security interests. While Comerica continues to make advances under the credit facility and the Company expects that advances will continue to be made, there can be no assurances that Comerica will exercise its discretion to make further advances or that Comerica will not accelerate the repayment of the indebtedness. Should Comerica not continue to provide advances under the credit facility, the Company would not have access to the funds needed to operate the Services business. In such event, the Company would be forced to consider alternative sources of liquidity to operate the business, which may require them to seek relief from a bankruptcy court or other reorganization proceeding to cause Comerica to provide access funds under the credit agreement.

Table of Contents

As of December 31, 2011, the Services Borrowers were not in compliance with all three of its loan covenants. See “Note 6 – Line of Credit” for a further discussion of the Comerica line of credit and non-compliance with covenants.

The Services Borrowers are presently in discussions with Comerica on the terms of a forbearance agreement related to the Comerica credit facility. In the interim, Comerica continues to provide funding to ASI and to pay certain corporate expenses of the Company. Comerica has released the $1,000,000 of restricted cash to fund the business operations. The Company believes it will enter into a forbearance agreement with Comerica and continue to access the Comerica credit facility while pursuing the strategic alternatives for the business discussed previously in “Note 2 – Management’s Plan”.

On April 23, 2010, the Company executed a Line of Credit and Security Agreement with H.D. Smith Wholesale Drug Co. (“HD Smith”), its new primary supplier of pharmaceutical products. Under terms of the agreement, PrairieStone was permitted to borrow up to $5,000,000, including amounts payable under normal product purchasing terms. Beginning April 1, 2011, borrowings under the agreement were limited based upon a borrowing base of the assets of the Pharmacy business. The debt accrues interest at the greater of 7% and the prime rate plus 3%. Interest during the first 12 months of the agreement will be capitalized and then interest only payments are required from May 2011 through April 2012. The debt is secured by all of the tangible and intangible assets of PrairieStone, a wholly-owned subsidiary of the Company that operates the Company’s Pharmacy segment. The agreement includes certain financial covenants beginning in fiscal 2012. In conjunction with the financing, the Company issued HD Smith warrants to purchase common stock, and the warrant terms are more fully described in “Note 8 – Stockholders’ Deficit”.

On September 29, 2011, the Company and PrairieStone received a letter from HD Smith indicating that PrairieStone was in default of its obligations under the HD Smith Credit Agreement. HD Smith declared all principal and accrued interest to be immediately due and payable. In lieu of exercising certain rights and remedies under the loan agreements, HD Smith, the Company and PrairieStone entered into a forbearance agreement dated October 6, 2011 (the "Forbearance Agreement"). During the Forbearance Period (as defined below), HD Smith agreed to forbear from exercising its rights under the HD Smith Credit Agreement for a limited period of time to permit the Company and PrairieStone to seek a purchaser for all of PrairieStone’s DailyMed business. On December 6, 2011 and simultaneous with the execution of the Asset Purchase Agreement more fully described in “Note 3 – Discontinued Operations”, the Company and PrairieStone entered into a Secured Creditor Assignment and Release Agreement (“Secured Creditor Agreement”) with HD Smith and Medication Adherence Solutions. The Secured Creditor Agreement provided for HD Smith to receive the $2.0 million cash payment contemplated in the purchase agreement. The Company received no cash proceeds from MAS as part of the transaction. Additionally, H.D. Smith assigned to MAS its right to payment of all amounts due under the H.D. Smith Credit Line, less the $2.0 million cash payment (“Assigned Claims”). MAS has agreed that it will not assert any claims or causes of action against PrairieStone or the Company to collect the Assigned Claims except under limited circumstances set forth in the Secured Creditor Agreement as set forth above in “Note 3 – Discontinued Operations”.

The Company has a limited number of customers with individually large amounts due at any given balance sheet date.

Recent Accounting Pronouncements

Please see Note 1 – Description of Company and Recent Accounting Pronouncements of this Report for recent accounting pronouncements that may have an impact on the Company’s consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The majority of our cash balances are held primarily in highly liquid commercial bank accounts. The Company utilizes lines of credit to fund operational cash needs. The risk associated with fluctuating interest rates is primarily limited to our borrowings. We do not believe that a 10% change in interest rates would have a significant effect on our results of operations or cash flows. All our revenues since inception have been in the U.S. and in U.S. Dollars; therefore, we have not yet adopted a strategy for the future currency rate exposure as it is not anticipated that foreign revenues are likely to occur in the near future.

Table of Contents

Item 4. Controls and Procedures.

The Company maintains a system of disclosure controls and procedures which are designed to ensure that information required to be disclosed by the Company in reports that it files or submits to the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including this report, is recorded, processed, summarized and reported on a timely basis. These disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed under the Exchange Act is accumulated and communicated to the Company’s management on a timely basis to allow decisions regarding required disclosure.

As of December 31, 2011, the Company’s management, including the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based on this evaluation, the CEO and CFO have concluded that the Company’s disclosure controls and procedures are effective.

There has been no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2011 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

We are a defendant from time to time in lawsuits incidental to our business in the ordinary course of business. Aside from the Douglas vs. Arcadia Health Services, Inc. matter described in “Note 9 – Contingencies” to the Consolidated Statements of Financial Condition, we are not currently subject to, and none of our subsidiaries are subject to, any material legal proceedings.

Item 1A. Risk Factors.

Immediate Risk Factors Associated With Recent Events

The Company’s financial position, high levels of debt and anticipated proceeds from the disposition of its operating segments make it highly unlikely that the common shares have any value.

The Company continues to generate negative cash flows on a consolidated basis. As of December 31, 2011, the Company has $44.5 million of outstanding debt, of which $40.0 million is due in or before April 2012. The Company has received a notice of default from its secured lender, Comerica Bank. As described in “Note 2 – Management’s Plan”, the Company sold its Pharmacy segment operations effective February 17, 2012 and is exploring the possible sale of its Services business. The proceeds from the sale of the Pharmacy segment were paid directly to the secured lender and the Company received no cash proceeds to apply to other debt obligations. If the Services segment is sold, we do not anticipate that the proceeds of such sale will to be sufficient to enable the Company to make any significant payments with respect to its unsecured debt. Additionally, it is possible that issues of liquidity or other factors could cause the Company to file a petition for relief under the United States Bankruptcy Code or initiate other reorganization proceedings.

For these reasons, investors are strongly discouraged from trading in shares of the Company’s common stock because it is highly unlikely that there is any equity value related to the common shares.

The Company's sole source of present funding is its line of credit with Comerica Bank, which is currently in default. Comerica's failure to provide on-going funding in the near-term would significantly impair the Company's ability to continue as a going concern.

The Company had negative cash flow from operations of $5,814,000 for the nine month period ended December 31, 2011. The Company continues to operate at a negative operating cash flow even after the sale of its Pharmacy segment. The Company is focused on improving operating results, reducing cash expenses and limiting cash outflows while at the same time looking for additional opportunities to generate short-term cash liquidity. Because the Company believes it has very limited access to traditional equity or debt markets, the Company’s alternatives for providing additional short-term liquidity are limited.

As of December 31, 2011, the Company had no available cash or line of credit under its revolving credit facility with Comerica Bank. In light of the Services Borrowers’ non-compliance with certain covenants under the line of credit facility, the availability of the Comerica Bank line of credit to fund operations is subject to the discretion of Comerica Bank.

The Company’s Board of Directors and management actively continue to evaluate alternative plans and strategies for addressing the Company’s short-term and long-term liquidity requirements. There can be no assurances, however, that the Company will be successful in these efforts. If the Company is unable to obtain additional cash to fund its current operations, there would be no assurance that the Company could continue as a going concern and the Company could be forced to file a petition for relief under the United States Bankruptcy Code or initiate other reorganization proceedings.

Our voluntary delisting from NYSE Amex and trading of our common stock in Over-the-Counter Markets could adversely affect the market price and liquidity of our common stock and the Company’s ability to raise additional capital.

In September 2011, the Company completed its voluntary delisting of its common stock from NYSE Amex and transition to the OTCQB Marketplace. There can be no assurance that an active trading market will continue to exist and our securities may experience price and volume fluctuations that may be more significant than when our securities were listed on NYSE Amex. As a result, a shareholder’s ability to sell shares of common stock, and the Company’s ability to raise additional capital through the issuance of common stock, may be adversely affected by the voluntarily delisting.

Table of Contents

Given the amount of debt due in April 2012 and our recurring losses from operations, we received a going concern opinion from our independent auditors, which could negatively affect our business and results of operation.

After conducting an audit of the Company’s consolidated financial statements for the fiscal year ended March 31, 2011, our independent auditors issued an unqualified opinion on the financial statements that included a material uncertainty related to our ability to continue as a going concern due to the amount of debt maturing in the near term and our recurring losses from operations, both of which could limit our ability to raise additional cash. The Company’s ability to continue as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis. The Company will need additional cash to fund operating activities during fiscal 2012. As indicated above, the Company’s ability to obtain additional financing is limited and the Company is highly dependent upon continued financing from Comerica Bank.

Our indebtedness could adversely affect our financial condition and operations, prevent us from fulfilling our debt service obligations and adversely affect our ability to operate our business.

As of December 31, 2011, we have $44.5 million of outstanding debt, of which $40.0 million matures in or prior to April 2012. As indicated above, the Company will not have the ability to pay off the debt maturing in April 2012 and it is highly unlikely that the Company will be able to refinance the debt. Unless the holders of the unsecured debt and the Company enter into agreements to extend the maturity of the debt, it is likely that the holders of the debt will have the right to declare events of default with respect to such indebtedness.

Even if the Company could extend the maturity of its existing debt, our indebtedness could have important consequences, including, but not limited to:

We may be unable to obtain additional financing for working capital, capital expenditures, acquisitions and general corporate or other purposes.

We may be unable to plan for, or react to, changes in our business and general market conditions.

We may be more vulnerable in a volatile market and at a competitive disadvantage to less leveraged competitors.

Our operating flexibility is more limited due to financial and other restrictive covenants, including restrictions on incurring additional debt, creating liens on our properties, making acquisitions and paying dividends.

We are subject to the risks that interest rates and our interest expense will increase.

Our ability to use operating cash flow in other areas of our business may be limited because we must dedicate a substantial portion of these funds to make principal and interest payments on our indebtedness.

Our ability to make investments or take other actions or borrow additional funds may be limited based on the financial and other restrictive covenants in our indebtedness.

The amount we are permitted to draw on our revolving credit facilities may be limited.

We may be forced to implement cost reductions, which could impact our product and service offerings.

We may be unable to successfully implement our growth strategy and spread our cost structure over a larger revenue base and ultimately become profitable.

The terms of our credit agreements with various lenders subject us to the risk of foreclosure on certain property.

Our wholly-owned subsidiary RKDA, Inc. granted Comerica Bank a first-priority security interest in all of the issued and outstanding capital stock of its wholly-owned subsidiary, Arcadia Services, Inc. and Arcadia Services, Inc. and its subsidiaries granted Comerica Bank security interests in all of their assets.

Arcadia Services, Inc. (“ASI”) and its subsidiaries are presently in default under the line of credit facility with Comerica Bank. Comerica Bank could at any time exercise its rights under the credit agreement to foreclose on the issued and outstanding shares of ASI and or the assets of ASI and/or its subsidiaries.

Risk Factors Associated With Business Segment Operations

A significant decline in sales in our Services business would adversely impact our revenue, operating income and cash flow and our ability to repay indebtedness and invest in new products and services.

Our Services segment has traditionally accounted for the majority of our revenue, operating profit and cash flow. There can be no assurance that this business will continue to generate cash flows at the levels generated in recent periods. Failure to achieve our sales targets in this market segment would adversely impact our revenue. While operating expense reductions and other actions would be taken in response to a decline in projected sales, such a reduction could adversely affect our projected operating income and cash flow.

Table of Contents

We depend on our affiliated agencies and our internal sales force to sell our services and products, the loss of which could adversely affect our business.

We rely upon our affiliated agencies and our internal sales force to sell our home care and medical staffing services and our internal sales force to sell our pharmacy products and services. Arcadia Services’ affiliated agencies are owner-operated businesses. The primary responsibilities of Arcadia Services’ affiliated agencies include the recruitment and training of field staff employed by Arcadia Services and generating and maintaining sales to Arcadia Services’ customers. The arrangements with affiliated agencies are formalized through a standard contractual agreement, which states performance requirements of the affiliated agencies. Our employees provide the services to our customers, and the affiliated agents and internal sales force are restricted by non-competition agreements. In the event of loss of our affiliated agents or internal sales force personnel, we would recruit new sales and marketing personnel and/or affiliated agents, which could cause our operating costs to increase and our sales to fall in the interim.

Sales of certain of our services and products are largely dependent upon payments from governmental programs and private insurance, and cost containment initiatives by these payers may reduce our revenues, thereby harming our performance.

In the U.S., healthcare providers and consumers who purchase home care services, prescription drug products and related products and services generally rely on third party payers, such as Medicare and Medicaid, to reimburse all or part of the cost of the healthcare product or service. Our sales and profitability are affected by the efforts of healthcare payers to contain or reduce the cost of healthcare by lowering reimbursement rates, limiting the scope of covered services, and negotiating reduced or capitated pricing arrangements. Any changes which lower reimbursement levels under Medicare, Medicaid or private pay programs, including managed care contracts, could reduce our future revenue. Furthermore, other changes in these reimbursement programs or in related regulations could reduce our future revenue. These changes may include modifications in the timing or processing of payments and other changes intended to limit or decrease the growth of Medicare, Medicaid or third party expenditures. In addition, our profitability may be adversely affected by any efforts of our suppliers to shift healthcare costs by increasing the net prices on the products we obtain from them.

The markets in which we operate are highly competitive and we may be unable to compete successfully against competitors with greater resources.

We compete in markets that are constantly changing, intensely competitive (given low barriers to entry), highly fragmented and subject to dynamic economic conditions. Increased competition is likely to result in price reductions, reduced gross margins, loss of customers, and loss of market share, any of which could adversely affect our net revenue and results of operations. Many of our competitors and potential competitors have more capital and marketing and technical resources than we do. These competitors and potential competitors include large drugstore chains, pharmacy benefits managers, on-line marketers, national wholesalers, and national and regional distributors. Further, the Company may face a significant competitive challenge from alliances entered into between and among its competitors, major HMO’s or chain drugstores, as well as from larger competitors created through industry consolidation. These potential competitors may be able to respond more quickly than we can to emerging market changes or changes in customer needs. To the extent competitors seek to gain or retain market share by reducing prices or increasing marketing expenditures, we could lose revenues or clients. In addition, relatively few barriers to entry exist in local healthcare markets. As a result, we could encounter increased competition in the future that may increase pricing pressure and limit our ability to maintain or increase our market share.

Negative publicity or changes in public perception of our services may adversely affect our ability to receive referrals, obtain new agreements and renew existing agreements.

Our success in receiving referrals, obtaining new agreements and renewing our existing agreements depends upon maintaining our reputation as a quality service provider among governmental authorities, physicians, hospitals, discharge planning departments, case managers, nursing homes, rehabilitation centers, advocacy groups, consumers and their families, other referral sources and the public. Negative publicity, changes in public perceptions of our services or government investigations of our operations could damage our reputation and hinder our ability to receive referrals, retain agreements or obtain new agreements. Increased government scrutiny may also contribute to an increase in compliance costs and could discourage consumers from using our services. Any of these events could have a negative effect on our business, financial condition and operating results.

Delays in reimbursement due to state budget deficits or otherwise have decreased, and may in the future further decrease, our liquidity.

There is generally a delay between the time that we provide services and the time that we receive reimbursement or payment for these services. A majority of states are facing budget deficits and other states may in the future delay reimbursement, which would adversely affect our liquidity. From time to time, procedural issues require us to resubmit claims before payment is remitted, which contributes to our aged receivables. Additionally, unanticipated delays in receiving reimbursement from state programs due to changes in their policies or billing or audit procedures may adversely impact our liquidity and working capital. Because we fund our operations primarily through the collection of accounts receivable, any delays in reimbursement would result in the need to increase borrowings under our credit facility.

Table of Contents

We are subject to extensive government regulation. Changes to the laws and regulations governing our business could negatively impact our profitability and any failure to comply with these regulations could adversely affect our business.

The federal government and the states in which we operate regulate our industry extensively. The laws and regulations governing our operations, along with the terms of participation in various government programs, impose certain requirements on the way in which we do business, the services we offer, and our interactions with consumers and the public. These requirements relate to:

•

Licensure and certification;

•

Adequacy and quality of health care services;

•

Qualifications and training of health care and support personnel;

•

Confidentiality, maintenance and security issues associated with medical records and claims processing;

•

Relationships with physicians and other referral sources;

•

Operating policies and procedures;

•

Addition of facilities and services; and

•

Billing for services.

These laws and regulations, and their interpretations, are subject to frequent change. These changes could reduce our profitability by increasing our liability, increasing our administrative and other costs, increasing or decreasing mandated services, forcing us to restructure our relationships with referral sources and providers or requiring us to implement additional or different programs and systems. Failure to comply could lead to the termination of rights to participate in federal and state-sponsored programs, the suspension or revocation of licenses and other civil and criminal penalties and a delay in our ability to bill and collect for services provided.

On March 23, 2010, the President signed into law the Health Reform Law. The Health Reform Law is broad, sweeping reform, and is subject to change, including through the adoption of related regulations, the way in which its provisions are interpreted and the manner in which it is enforced. We cannot assure you that such provisions of the Health Reform Law, will not adversely impact our business, results of operations or financial results. We may be unable to mitigate any adverse effects resulting from the Health Reform Act.

The HITECH Act established certain health information security breach notification requirements. A covered entity must notify any individual whose protected health information is breached. While we believe that we protect individuals’ health information, if our information systems are breached, we may experience reputational harm that could adversely affect our business. In addition, failure to comply with the HITECH Act could result in fines and penalties that could have a material adverse effect on us.

We are subject to reviews, compliance audits and investigations that could result in adverse findings that negatively affect our net service revenues and profitability.

As a result of our participation in Medicaid and other governmental programs, and pursuant to certain of our contractual relationships, we are subject to various reviews, audits and investigations by governmental authorities and other third parties to verify our compliance with these programs and agreements as well as applicable laws, regulations and conditions of participation. If we fail to meet any of the conditions of participation or coverage, we may receive a notice of deficiency from the applicable surveyor or authority. Failure to institute a plan of action to correct the deficiency within the period provided by the surveyor or authority could result in civil or criminal penalties, the imposition of fines or other sanctions, damage to our reputation, cancellation of our agreements, suspension or revocation of our licenses or disqualification from federal and state reimbursement programs. These actions may adversely affect our ability to provide certain services, to receive payments from other payors and to continue to operate. Additionally, actions taken against one of our locations may subject our other locations to adverse consequences. Any termination of one or more of our locations from a government program for failure to satisfy such program’s conditions of participation could adversely affect our net service revenues and profitability.

Payments we receive in respect of Medicaid can be retroactively adjusted after a new examination during the claims settlement process or as a result of pre- or post-payment audits. Federal, state and local government payors may disallow our requests for reimbursement based on determinations that certain costs are not reimbursable because proper documentation was not provided or because certain services were not covered or deemed necessary. In addition, other third-party payors may reserve rights to conduct audits and make reimbursement adjustments in connection with or exclusive of audit activities. Significant adjustments as a result of these audits could adversely affect our revenues and profitability.

Table of Contents

Changes in federal and state laws that govern our financial relationships with physicians and other health care providers may impact potential or current referral sources.

We offer certain healthcare-related products and services that are subject to federal and state laws restricting our relationship with physicians and other healthcare providers. Generally referred to as “anti-kickback laws,” these laws prohibit certain direct and indirect payments or other financial arrangements that are designed to encourage the referral of patients to a particular medical services provider. In addition, certain financial relationships, including ownership interests and compensation arrangements, between physicians and providers of designated health services, such as our Company, to whom those physicians refer patients, are prohibited by the federal physician self-referral prohibition, known as the “Stark Law,” and similar state laws. Violations of these laws could lead to fines or sanctions that could have a material adverse effect on our business. In addition, changes in healthcare law or new interpretations of existing laws may have a material impact on our business and results of operations.

We are required to comply with laws governing the transmission of privacy of health information.

The Health Insurance Portability and Accountability Act of 1996, or HIPAA, requires us to comply with standards for the exchange of health information within our Company and with third parties, such as payers, business associates and consumers. These include standards for common health care transactions, such as claims information, plan eligibility, payment information, the use of electronic signatures, unique identifiers for providers, employers, health plans and individuals and security, privacy and enforcement. New standards and regulations may be adopted governing the use, disclosure and transmission of health information with which we may be required to comply. We could be subject to criminal penalties and civil sanctions if we fail to comply with these standards. In addition, compliance with new standards and regulations could increase our costs and adversely affect our results of operations.

Because we depend on key management, the loss of the services or advice of any of these persons could have a material adverse effect on our business and prospects.

Our success is dependent on our ability to attract and retain qualified and experienced management and personnel. We do not presently maintain key person life insurance for any of our personnel. There can be no assurance that we will be able to attract and retain key personnel in the future, and our inability to do so could have a material adverse effect on us. Our management team will need to work together effectively to successfully develop and implement our business strategies and financial operations. In addition, management will need to devote significant attention and resources to preserve and strengthen relationships with employees, customers and the investor community. If our management team is unable to achieve these goals, our ability to grow our business and successfully meet operational challenges could be impaired.

We do not have long-term agreements or exclusive guaranteed order contracts with our home care, hospital and healthcare facility clients.

The success of our Services business depends upon our ability to continually secure new orders from home care clients, hospitals and other healthcare facilities and to fill those orders with our temporary healthcare professionals. We do not have long-term agreements or exclusive guaranteed order contracts with our home care, hospital and health care facility clients. We rely on our agencies to establish and maintain positive relationships with these clients. If we, or our agents, fail to maintain positive relationships with our home care, hospital and healthcare facility clients, we may be unable to generate new temporary healthcare professional orders and our business may be adversely affected. In addition, many of these clients may have devised strategies to reduce the expenditures on temporary healthcare workers and to limit overall agency utilization. If current pressures to control agency usage continue and escalate, we will have fewer business opportunities, which could harm our business.

Our operations subject us to risk of litigation.

Operating in the homecare industry exposes us to an inherent risk of wrongful death, personal injury, professional malpractice and other potential claims or litigation brought by our consumers and employees. These claims may include, for example, allegations that we did not properly treat or care for a consumer or that we failed to follow internal or external procedures that resulted in death or harm to a consumer.

In addition, regulatory agencies may initiate administrative proceedings alleging violations of statutes and regulations arising from our services and seek to impose monetary penalties on us. We could be required to pay substantial amounts to respond to regulatory investigations or, if we do not prevail, damages or penalties arising from these legal proceedings. We also are subject to potential lawsuits under the False Claims Act or other federal and state whistleblower statutes designed to combat fraud and abuse in our industry. These lawsuits can involve significant monetary awards or penalties which may not be covered by our insurance. If our third-party insurance coverage and self-insurance reserves are not adequate to cover these claims, it could have a material adverse effect on our business, results of operations and financial condition. Even if we are successful in our defense, civil lawsuits or regulatory proceedings could distract management from running our business or irreparably damage our reputation.

Table of Contents

Other Risk Factors Associated with the Company’s Capital Structure and Financing

We cannot predict the impact that registration of shares may have on the price of our common stock.

We cannot predict the impact, if any, that sales of, or the availability for sale of, shares of our common stock by selling security holders pursuant to a prospectus or otherwise will have on the market price of our securities prevailing from time to time. The possibility that substantial amounts of our common stock might enter the public market could adversely affect the prevailing market price of our common stock and could impair our ability to fund acquisitions or to raise capital in the future through the sales of securities. Sales of substantial amounts of our securities, including shares issued upon the exercise of options or warrants, or the perception that such sales could occur, could adversely affect prevailing market prices for our securities.

The price of our common stock has been, and will likely continue to be, volatile, which could diminish the ability to recoup an investment, or to earn a return on an investment, in our common stock.

The market price of our common stock has fluctuated over a wide range, and it is likely that it will continue to do so in the future. Limited demand for our common stock has resulted in limited liquidity, and it may be difficult to dispose of our securities. Due to the volatility of the price of our common stock, an investor may be unable to resell shares of our common stock at or above the price paid for them, thereby exposing an investor to the risk that he may not recoup an investment in our common stock or earn a return on such an investment. In the past, securities class action litigation has been brought against companies following periods of volatility in the market price of their securities. If we are the target of similar litigation in the future, we would be exposed to incurring significant litigation costs. This would also divert management’s attention and resources, all of which could substantially harm our business and results of operations.

Resale of our securities by any holder may be limited and affected by state blue-sky laws, which could adversely affect the price of our securities and the holder’s investment in our Company.

Under the securities laws of some states, shares of common stock and warrants can be sold in such states only through registered or licensed brokers or dealers. In addition, in some states, warrants and shares of common stock may not be sold unless these shares have been registered or qualified for sale in the state or an exemption from registration or qualification is available and is complied with. The requirement of a seller to comply with the requirements of state blue sky laws may lead to delay or inability of a holder of our securities to dispose of such securities, thereby causing an adverse effect on the resale price of our securities.

The issuance of our preferred stock could materially impact the market price of our common stock and the rights of holders of our common stock.

We are authorized to issue 5,000,000 shares of serial preferred stock, par value $0.001. Shares of preferred stock may be issued from time to time in one or more series as may be determined by our Board of Directors. Except as otherwise provided in our Restated Articles of Incorporation, the Board of Directors has the authority to fix by resolution adopted before the issuance of any shares of each particular series of preferred stock, the designation, powers, preferences, and relative participating, optional redemption and other rights, and the qualifications, limitations, and restrictions of that series. The issuance of our preferred stock could materially impact the price of our common stock and the rights of holders of our common stock, including voting rights. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to holders of common stock, and may have the effect of delaying, deferring or preventing a change in control of our company, despite such change of control being in the best interest of the holders of our common stock. The existence of authorized but unissued preferred stock may enable the Board of Directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.

The exercise of common stock warrants and stock options may depress our stock price and may result in dilution to our common security holders.

Warrants to purchase approximately 9.7 million shares of our common stock were issued and outstanding as of December 31, 2011. Options to purchase approximately 8.2 million shares of our common stock were issued and outstanding as of December 31, 2011. The Arcadia Resources, Inc. 2006 Equity Incentive Plan (the “Plan”), as amended on October 14, 2009, allows for the granting of additional incentive stock options, non-qualified stock options, stock appreciation rights and restricted shares up to 15 million shares (5.0% of our authorized shares of common stock as of the date the Plan was approved), of which the Company had available approximately 4.2 million shares as of December 31, 2011 for future grants.

If the market price of our common stock is above the exercise price of some of the outstanding warrants or options; the holders of those warrants or options may exercise their warrants or options and sell the common stock they acquire upon exercise in the public market. Sales of a substantial number of shares of our common stock in the public market may depress the prevailing market price for our common stock and could impair our ability to raise capital through the future sale of our equity securities. Additionally, if the holders of outstanding warrants exercise those warrants, our common security holders will suffer dilution in their voting power. The exercise price and the number of shares subject to the warrant or option is subject to adjustment upon stock dividends, splits and combinations, as well as certain anti-dilution adjustments as set forth in the respective common stock warrants.

Table of Contents

Several anti-takeover measures under Nevada law could delay or prevent a change of control, despite such change of control being in the best interest of the holders of our common stock.

Several anti-takeover measures under Nevada law could delay or prevent a change of control, despite such change of control being in the best interest of the holders of our common stock. This could make it more difficult or discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. This could negatively impact the value of an investment in our common stock, by discouraging a potential suitor who may otherwise be willing to offer a premium for shares of our common stock.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 5. Other Information

On February 17, 2012, the Company and PrairieStone Pharmacy LLC (“PrairieStone”) completed the sale of substantially all of the assets of the Company’s Pharmacy segment to Medication Adherence Solutions, LLC (“MAS”) pursuant to the Asset Purchase Agreement dated December 6, 2011 by and between the Company, PrairieStone and MAS. The APA was filed as an exhibit to the Company’s Form 8-K filed on December 6, 2011. For a discussion of the terms of the transaction, see “Note 3 – Discontinued Operation” above.

Item 6. Exhibits.

The Exhibits included as part of this report are listed in the attached Exhibit Index, which is incorporated herein by this reference.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

February 20, 2012	By:	/s/ Marvin R. Richardson
		Marvin R. Richardson
		Chief Executive Officer
		(Principal Executive Officer) and Director

February 20, 2012	By:	/s/ Matthew R. Middendorf
		Matthew R. Middendorf
		Treasurer and Chief Financial Officer
		(Principal Financial and Accounting Officer)

Table of Contents

EXHIBIT INDEX

The following documents are filed as part of this report. Exhibits not required for this report have been omitted. The Company’s Commission file number is 000-32935.

Exhibit No.		Exhibit Description
2.1		Asset Purchase Agreement, incorporated by reference to Exhibit 2.01to the Registrant’s Current report on Form 8-K filed December 6, 2011.
10.1		Forbearance Agreement dated October 6, 2011, by and among PrairieStone Pharmacy, LLC, Arcadia Resources, Inc. and H.D. Smith Wholesale Drug Co.
10.2		Amendment 1 dated November 18, 2011 to the Forbearance Agreement dated October 6, 2011 by and among H. D. Smith Wholesale Drug Co., Arcadia Resources, Inc. and PrairieStone Pharmacy, LLC
10.3		Amendment 2 dated November 30, 2011 to the Forbearance Agreement dated October 6, 2011 by and among H. D. Smith Wholesale Drug Co., Arcadia Resources, Inc. and PrairieStone Pharmacy, LLC
10.4		Settlement Agreement and General Release dated November 8, 2011, by and among Plaintiff Ruth L. Douglas, individually and on behalf of others similarly situated, and Defendant Arcadia Health Services, Inc.
10.5		Secured Creditor Assignment and Release Agreement dated December 6, 2011, by and among H. D. Smith Wholesale Drug Co., Arcadia Resources, Inc., PrairieStone Pharmacy, LLC and Medication Adherence Solutions, LLC
31.1		Certification of the Chief Executive Officer required by rule 13a — 14(a) or rule 15d — 14(a).
31.2		Certification of the Principal Accounting and Financial Officer required by rule 13a — 14(a) or rule 15d — 14(a).
32.1		Chief Executive Officer Certification Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to §906 of the Sarbanes — Oxley Act of 2002.
32.2		Principal Accounting and Financial Officer Certification Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to §906 of the Sarbanes — Oxley Act of 2002.

ARCADIA RESOURCES, INC 10-Q